SK1522000A3 - Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists - Google Patents
Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists Download PDFInfo
- Publication number
- SK1522000A3 SK1522000A3 SK152-2000A SK1522000A SK1522000A3 SK 1522000 A3 SK1522000 A3 SK 1522000A3 SK 1522000 A SK1522000 A SK 1522000A SK 1522000 A3 SK1522000 A3 SK 1522000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- alkyl
- phenyl
- substituted
- alkoxy
- alkylthio
- Prior art date
Links
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title claims abstract description 12
- 229940118365 Endothelin receptor antagonist Drugs 0.000 title abstract description 4
- 239000002308 endothelin receptor antagonist Substances 0.000 title abstract description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 117
- -1 alkali metal cation Chemical class 0.000 claims description 115
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 20
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 239000011593 sulfur Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 12
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 125000001624 naphthyl group Chemical group 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 229910052783 alkali metal Inorganic materials 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000005466 alkylenyl group Chemical group 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- FONOSWYYBCBQGN-UHFFFAOYSA-N ethylene dione Chemical group O=C=C=O FONOSWYYBCBQGN-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 229910005965 SO 2 Inorganic materials 0.000 claims description 3
- 125000004450 alkenylene group Chemical group 0.000 claims description 3
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims 4
- 125000005133 alkynyloxy group Chemical group 0.000 claims 1
- 150000005840 aryl radicals Chemical class 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 31
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 108050009340 Endothelin Proteins 0.000 description 12
- 102000002045 Endothelin Human genes 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000027455 binding Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 150000002170 ethers Chemical class 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 5
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- NUKZAGXMHTUAFE-UHFFFAOYSA-N methyl hexanoate Chemical compound CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101800004490 Endothelin-1 Proteins 0.000 description 3
- 102400000686 Endothelin-1 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- MJXSDNAEQWGZGP-UHFFFAOYSA-N 2-hydroxy-3-methoxy-3,6-diphenylhexanoic acid Chemical compound C=1C=CC=CC=1C(OC)(C(O)C(O)=O)CCCC1=CC=CC=C1 MJXSDNAEQWGZGP-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- SENQOFMCFSPGJF-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-hydroxy-3-phenylhexanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCCC(C=1C=CC=CC=1)(C(O)C(O)=O)OCCC1=CC=C(OC)C(OC)=C1 SENQOFMCFSPGJF-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000010180 Endothelin receptor Human genes 0.000 description 2
- 108050001739 Endothelin receptor Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 208000001286 intracranial vasospasm Diseases 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- MTDIXZBROJJEMX-UHFFFAOYSA-N methyl 3-phenyl-3-(3-phenylpropyl)oxirane-2-carboxylate Chemical compound COC(=O)C1OC1(C=1C=CC=CC=1)CCCC1=CC=CC=C1 MTDIXZBROJJEMX-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- 125000004711 1,1-dimethylethylthio group Chemical group CC(C)(S*)C 0.000 description 1
- GBUMEGLMTNAXOM-UHFFFAOYSA-N 1,4-diphenylbutan-1-one Chemical compound C=1C=CC=CC=1C(=O)CCCC1=CC=CC=C1 GBUMEGLMTNAXOM-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004781 2,2-dichloro-2-fluoroethyl group Chemical group [H]C([H])(*)C(F)(Cl)Cl 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- KPTPREQPJGCQBH-UHFFFAOYSA-N 2-(4,6-dimethylpyrimidin-2-yl)oxy-3,6-diphenyl-3-[2-(3,4,5-trimethoxyphenyl)ethoxy]hexanoic acid Chemical compound COc1cc(CCOC(CCCc2ccccc2)(C(Oc2nc(C)cc(C)n2)C(O)=O)c2ccccc2)cc(OC)c1OC KPTPREQPJGCQBH-UHFFFAOYSA-N 0.000 description 1
- QCVQVCPERSIFJU-UHFFFAOYSA-N 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-(4-methoxyphenoxy)-3,6-diphenylhexanoic acid Chemical compound COc1ccc(OC(CCCc2ccccc2)(C(Oc2nc(C)cc(C)n2)C(O)=O)c2ccccc2)cc1 QCVQVCPERSIFJU-UHFFFAOYSA-N 0.000 description 1
- AMTCWKOTBYLRBD-UHFFFAOYSA-N 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,6-diphenylhexanoic acid Chemical compound N=1C(C)=CC(C)=NC=1OC(C(O)=O)C(C=1C=CC=CC=1)(OC)CCCC1=CC=CC=C1 AMTCWKOTBYLRBD-UHFFFAOYSA-N 0.000 description 1
- DZJCKEJIFNQWSP-UHFFFAOYSA-N 2-(4-methoxy-6-methylpyrimidin-2-yl)oxy-3,6-diphenyl-3-[2-(3,4,5-trimethoxyphenyl)ethoxy]hexanoic acid Chemical compound COC1=CC(C)=NC(OC(C(O)=O)C(CCCC=2C=CC=CC=2)(OCCC=2C=C(OC)C(OC)=C(OC)C=2)C=2C=CC=CC=2)=N1 DZJCKEJIFNQWSP-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000004780 2-chloro-2,2-difluoroethyl group Chemical group [H]C([H])(*)C(F)(F)Cl 0.000 description 1
- 125000004791 2-fluoroethoxy group Chemical group FCCO* 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- OWERJMBAZKUAGS-UHFFFAOYSA-N 3-[(3,4-dimethoxyphenyl)methoxy]-2-(4-methoxy-6-methylpyrimidin-2-yl)oxy-3,6-diphenylhexanoic acid Chemical compound COc1cc(C)nc(OC(C(O)=O)C(CCCc2ccccc2)(OCc2ccc(OC)c(OC)c2)c2ccccc2)n1 OWERJMBAZKUAGS-UHFFFAOYSA-N 0.000 description 1
- GKGRDCADRYKKPO-UHFFFAOYSA-N 3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(4-methoxy-6-methylpyrimidin-2-yl)oxy-3,6-diphenylhexanoic acid Chemical compound COC1=CC(C)=NC(OC(C(O)=O)C(CCCC=2C=CC=CC=2)(OCCC=2C=C(OC)C(OC)=CC=2)C=2C=CC=CC=2)=N1 GKGRDCADRYKKPO-UHFFFAOYSA-N 0.000 description 1
- MVZSVIWKRHKBFP-UHFFFAOYSA-N 3-[2-(4-hydroxy-3-methoxyphenyl)ethoxy]-2-(4-methoxy-6-methylpyrimidin-2-yl)oxy-3,6-diphenylhexanoic acid Chemical compound COC1=CC(C)=NC(OC(C(O)=O)C(CCCC=2C=CC=CC=2)(OCCC=2C=C(OC)C(O)=CC=2)C=2C=CC=CC=2)=N1 MVZSVIWKRHKBFP-UHFFFAOYSA-N 0.000 description 1
- QSNKQHXTPVICBY-UHFFFAOYSA-N 3-methoxy-2-(4-methoxy-6-methylpyrimidin-2-yl)oxy-3,6-diphenylhexanoic acid Chemical compound COC1=CC(C)=NC(OC(C(O)=O)C(CCCC=2C=CC=CC=2)(OC)C=2C=CC=CC=2)=N1 QSNKQHXTPVICBY-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- LHXVWEHJQRXCIW-UHFFFAOYSA-N 4-[[1-carboxy-1-(4,6-dimethylpyrimidin-2-yl)oxy-2,5-diphenylpentan-2-yl]oxymethyl]benzoic acid Chemical compound CC1=CC(C)=NC(OC(C(O)=O)C(CCCC=2C=CC=CC=2)(OCC=2C=CC(=CC=2)C(O)=O)C=2C=CC=CC=2)=N1 LHXVWEHJQRXCIW-UHFFFAOYSA-N 0.000 description 1
- QNCXYVGMOBWGQT-UHFFFAOYSA-N 4-[[1-carboxy-1-(4-methoxy-6-methylpyrimidin-2-yl)oxy-2,5-diphenylpentan-2-yl]oxymethyl]benzoic acid Chemical compound COC1=NC(=NC(=C1)C)OC(C(=O)O)C(CCCC1=CC=CC=C1)(C1=CC=CC=C1)OCC1=CC=C(C=C1)C(=O)O QNCXYVGMOBWGQT-UHFFFAOYSA-N 0.000 description 1
- GNAQBURBJPHPGP-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-(4-methoxyphenoxy)-3-phenylhexanoic acid Chemical compound COc1ccc(OC(CCCc2ccc(OC)c(OC)c2)(C(Oc2nc(C)cc(C)n2)C(O)=O)c2ccccc2)cc1 GNAQBURBJPHPGP-UHFFFAOYSA-N 0.000 description 1
- WHSTUVISWMACTM-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-phenylhexanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCCC(C=1C=CC=CC=1)(C(OC=1N=C(C)C=C(C)N=1)C(O)=O)OCCC1=CC=C(OC)C(OC)=C1 WHSTUVISWMACTM-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- NDIIGIGBLACPNU-UHFFFAOYSA-N C1=CC=C(C=C1)CCCC(C2=CC=CC=C2)C(C(=O)O)OCCC3=CC=CS3 Chemical compound C1=CC=C(C=C1)CCCC(C2=CC=CC=C2)C(C(=O)O)OCCC3=CC=CS3 NDIIGIGBLACPNU-UHFFFAOYSA-N 0.000 description 1
- YKFRGYORNHGJOL-FYJGNVAPSA-N CC1=CC(=NC(=N1)OC(C(=O)O)C(CCCC2=CC=CC=C2)(C3=CC=CC=C3)O/C=C/CC4=CC(=C(C(=C4)OC)OC)OC)C Chemical compound CC1=CC(=NC(=N1)OC(C(=O)O)C(CCCC2=CC=CC=C2)(C3=CC=CC=C3)O/C=C/CC4=CC(=C(C(=C4)OC)OC)OC)C YKFRGYORNHGJOL-FYJGNVAPSA-N 0.000 description 1
- UTXWEWXWUSYBBB-UHFFFAOYSA-N CC1=NC(=NC(=C1)C)OC(C(=O)O)C(CCCC1=CC(=C(C=C1)OC)OC)(C1=CC=CC=C1)OC Chemical compound CC1=NC(=NC(=C1)C)OC(C(=O)O)C(CCCC1=CC(=C(C=C1)OC)OC)(C1=CC=CC=C1)OC UTXWEWXWUSYBBB-UHFFFAOYSA-N 0.000 description 1
- NTFJFXHPHZUZDN-UHFFFAOYSA-N CC1=NC(=NC(=C1)C)OC(C(=O)O)C(CCCC1=CC=CC=C1)(C1=CC=CC=C1)OCC1=CC(=C(C=C1)OC)OC Chemical compound CC1=NC(=NC(=C1)C)OC(C(=O)O)C(CCCC1=CC=CC=C1)(C1=CC=CC=C1)OCC1=CC(=C(C=C1)OC)OC NTFJFXHPHZUZDN-UHFFFAOYSA-N 0.000 description 1
- SVSOIQVXTQCIRX-UHFFFAOYSA-N COC1=NC(=NC(=C1)C)OC(C(=O)O)C(CCCC1=CC=CC=C1)(C1=CC=CC=C1)OC1=CC=C(C=C1)OC Chemical compound COC1=NC(=NC(=C1)C)OC(C(=O)O)C(CCCC1=CC=CC=C1)(C1=CC=CC=C1)OC1=CC=C(C=C1)OC SVSOIQVXTQCIRX-UHFFFAOYSA-N 0.000 description 1
- QQOJAUDHRJYJLM-UHFFFAOYSA-N COc1cc(CCOC(CCCc2ccccc2)(C(Oc2nc(C)cc(C)n2)C(O)=O)c2ccccc2)ccc1O Chemical compound COc1cc(CCOC(CCCc2ccccc2)(C(Oc2nc(C)cc(C)n2)C(O)=O)c2ccccc2)ccc1O QQOJAUDHRJYJLM-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100040611 Endothelin receptor type B Human genes 0.000 description 1
- 102100029110 Endothelin-2 Human genes 0.000 description 1
- 108090000387 Endothelin-2 Proteins 0.000 description 1
- 102100029109 Endothelin-3 Human genes 0.000 description 1
- 108010072844 Endothelin-3 Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- IAGQFHHWGXKSBG-UHFFFAOYSA-N OC(C(=O)OC)C(CCCC1=CC(=C(C=C1)OC)OC)(C1=CC=CC=C1)OCCC1=CC(=C(C=C1)OC)OC Chemical compound OC(C(=O)OC)C(CCCC1=CC(=C(C=C1)OC)OC)(C1=CC=CC=C1)OCCC1=CC(=C(C=C1)OC)OC IAGQFHHWGXKSBG-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 206010059799 Prostatic hypoplasia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- QABLOFMHHSOFRJ-UHFFFAOYSA-N methyl 2-chloroacetate Chemical compound COC(=O)CCl QABLOFMHHSOFRJ-UHFFFAOYSA-N 0.000 description 1
- ICDXHLFZNFUENS-UHFFFAOYSA-N methyl 2-hydroxy-3-methoxy-3,6-diphenylhexanoate Chemical compound C=1C=CC=CC=1C(C(O)C(=O)OC)(OC)CCCC1=CC=CC=C1 ICDXHLFZNFUENS-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WJWOJXJNPRGALQ-AATRIKPKSA-N n1c(C)cc(C)nc1OC(C(O)=O)C(CCCc1ccccc1)(OCC/C=C/CC)c1ccccc1 Chemical compound n1c(C)cc(C)nc1OC(C(O)=O)C(CCCc1ccccc1)(OCC/C=C/CC)c1ccccc1 WJWOJXJNPRGALQ-AATRIKPKSA-N 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
Deriváty karboxylových kyselín, ich príprava a použitie ako zmesn^antagonistcV ETa/ETb endotelínového receptoraCarboxylic acid derivatives, their preparation and use as mixed endothelin receptor ETa / ETb antagonists
Oblasť technikyTechnical field
Predložený vynález sa týka nových derivátov karboxylových kyselín, ich prípravy a použitia.The present invention relates to novel carboxylic acid derivatives, their preparation and use.
Doterajší stav technikyBACKGROUND OF THE INVENTION
Endotelín je peptid, ktorý sa skladá z 21 aminokyselín sa syntetizuje a uvoľňuje bunečnou výstelkou ciev. Endotelín jestvuje v troch izoformách, ET-1, ET-2 a ET-3. Endotelín“ alebo “ET“, ako sa uvádza ďalej, sa vzťahuje na jednu alebo všetky izoformy endotelínu. Endotelín je účinným vazokonštriktorom a má silný účinok na tonus ciev. Je známe, že táto vazokonštrikcia je spôsobená viazaním endotelínu k jeho receptoru (Náture, 332 (1988) 411-415; FEBS Letters, 231 (1988) 440-444 a Biochem. Biophys. Res. Commun., 154 (1988) 868-875).Endothelin is a peptide consisting of 21 amino acids synthesized and released by the vascular endothelium. Endothelin exists in three isoforms, ET-1, ET-2 and ET-3. Endothelin 'or' ET ', as described below, refers to one or all isoforms of endothelin. Endothelin is a potent vasoconstrictor and has a potent effect on vascular tone. This vasoconstriction is known to be due to the binding of endothelin to its receptor (Nature, 332 (1988) 411-415; FEBS Letters, 231 (1988) 440-444 and Biochem. Biophys. Res. Commun., 154 (1988) 868-). 875).
Zvýšené alebo abnormálne uvoľňovanie endotelínu spôsobuje pretrvávajúcu vazokonštrikciu v periferálnych, renálnych a cerebrálnych krvných cievach, čo môže viesť k ochoreniam. V literatúre sa uvádza, že endotelín sa podieľa na celom rade ochorení. Medzi tieto patrí hypertenzia, akútny infarkt myokardu, pulmonálna hypertenzia, Raynaudov syndróm, cerebrálny vazospazmus, mŕtvica, benígna hypertrofia prostaty, ateroskleróza a astma (J. Vascular Med. Biology 2 (1990) 207, J. Am. Med. Association 264 (1990) 2868, Náture 344 (1990) 114, N. Eg. J. Med. 322 (1989) 205, N. eg.. J. Med. 328 (1993) 1732, Nephron 66 (1994) 373, Strake 25 (1994) 904, Náture 365 (1993) 759, J. Mol. Celí. Cardiol. 27 (1995) A234; Cancer Research 56 (1996) 663).Increased or abnormal release of endothelin causes persistent vasoconstriction in peripheral, renal and cerebral blood vessels, which can lead to disease. It is reported in the literature that endothelin is involved in a number of diseases. These include hypertension, acute myocardial infarction, pulmonary hypertension, Raynaud's syndrome, cerebral vasospasm, stroke, benign prostate hypertrophy, atherosclerosis and asthma (J. Vascular Med. Biology 2 (1990) 207, J. Am. Med. Association 264 (1990) 2868, Nature 344 (1990) 114, N. Eg J. Med 322 (1989) 205, N. Eg J. Med 328 (1993) 1732, Nephron 66 (1994) 373, Strake 25 (1994) 904, Nature 365 (1993) 759, J Mol Cell Cardiol 27 (1995) A234; Cancer Research 56 (1996) 663).
Uvedená literatúra opisuje najmenej dva podtypy receptorov endotelínu, ETa a ETb receptory, (Náture 348 (1990) 730 a 732). Podľa uvedeného, látky, ktoré inhibujú viazanie endotelínu ku dvom receptorom musia antagonizovať fyziologické účinky endotelínu a preto predstavujú hodnotné liečivá.The literature describes at least two endothelin receptor subtypes, the ETα and ETb receptors, (Nature 348 (1990) 730 and 732). Accordingly, agents that inhibit the binding of endothelin to the two receptors must antagonize the physiological effects of endothelin and therefore represent valuable drugs.
WO 96/11914 opisuje deriváty karboxylových kyselín, ktoré sa však s vysokou afinitou viažu k ETa receptoru a so značne nižšou afinitou k ETb receptoru (nazývaným ETA-špecifické antagonisty).WO 96/11914 discloses carboxylic acid derivatives which, however, bind with a high affinity to the ETα receptor and with a much lower affinity for the ETb receptor (called ETA-specific antagonists).
-2Hovoríme o antagonistoch ako ETA-špecifických, ak ich afinita pre ETA receptor je najmenej desaťkrát vyššia ako ich afinita pre ETB receptor.We are talking about antagonists as ET A -specific if their affinity for the ET A receptor is at least ten times higher than their affinity for the ET B receptor.
Predmetom predloženého vynálezu je poskytnúť antagonisty endotelínového receptora ktoré sa viažu približne s rovnakou afinitou ku ETAa ETB receptorom (nazývaným zmesné antagonisty).It is an object of the present invention to provide endothelin receptor antagonists that bind with approximately the same affinity to ET A and ET B receptors (called mixed antagonists).
Približne rovnaká afinita pre receptory znamená, že pomer afinít je väčší ako 0,1 a menší ako 1,0.Approximately the same affinity for receptors means that the affinity ratio is greater than 0.1 and less than 1.0.
Podstata vynálezuSUMMARY OF THE INVENTION
Vynález sa týka derivátov karboxylových kyselín všeobecného vzorca IThe invention relates to carboxylic acid derivatives of the general formula I
Ή — O —Het kde substituenty majú nasledujúce významy R znamená tetrazol alebo skupinu predstavuje zvyšok OR7, v ktoromKde - O — Het wherein the substituents have the following meanings R represents tetrazole or the group represents the radical OR 7 in which
R7 znamená vodík, katión alkalického kovu, katión kovu alkalickej zeminy alebo fýziologicky prijateľný organický amóniový ión;R 7 is hydrogen, an alkali metal cation, an alkaline earth metal cation or a physiologically acceptable organic ammonium ion;
C3-C8-cykloalkyl, Ci—Ce—alkyl;C 3 -C 8 -cycloalkyl, C 1 -C 6 -alkyl;
CHz-fenyl, nesubstituovaný alebo substituovaný;CH2-phenyl, unsubstituted or substituted;
C3-C6-alkenylovú alebo C3-C6-alkinylovú skupinu, nesubstituovanú alebo substituovanú; alebo fenyl, nesubstituovaný alebo substituovaný,C3-C6-alkenyl or C3-C6-alkynyl, unsubstituted or substituted; or phenyl, unsubstituted or substituted,
-3R2 predstavuje vodík, hydroxylovú skupinu, NH2, NHÍC^C^alkyl), N(Ci-C4alkyl)2, halogén, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, Ci-C4halogénalkyl, Ci-C4-alkoxy, Ci-C4-halogénalkoxy alebo Ci—C4—alkyltio, alebo CR je viazane k CR ako je uvedené nižšie, za vzniku 5- alebo 6členného kruhu, alebo ak Het znamená päťčlenný kruh, CR2 môže spolu s CR3 predstavovať 5- alebo 6-členný alkenylový alebo alkylenylový kruh, ktorý je nesubstituovaný alebo substituovaný;-3R 2 is H, OH, NH 2, NHÍC ^ C ^ alkyl), N (Ci-C4 alkyl) 2, halo, C 4 alkyl, C 2 -C 4 -alkenyl, C 2 -C 4 - alkynyl, C 1 -C 4 haloalkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -haloalkoxy or C 1 -C 4 -alkylthio, or CR is bound to CR as shown below to form a 5- or 6-membered ring, or when Het represents a five membered ring, CR 2 together with CR 3 can represent a 5- or 6-membered alkenyl or alkylenyl ring which is unsubstituted or substituted;
X znamená dusík alebo metín;X is nitrogen or methine;
Y predstavuje dusík alebo metin;Y is nitrogen or methine;
W znamená dusík alebo CR10, kde R10 predstavuje vodík alebo CM-alkyl, alebo CR10 tvorí spolu s CR2 alebo CR3 5- alebo 6-členný alkylénový alebo alkenylénový kruh, ktorý je nesubstituovaný alebo substituovaný a v ktorom v každom prípade jedna alebo viac metylénových skupín môže byť nahradených substituentom ako je kyslík, síra, -NH alebo -NíC-i-C^alkyl);W is nitrogen or CR 10 wherein R 10 is hydrogen or C M alkyl, or CR10 forms together with CR2 or CR3 a 5- or 6-membered alkylene or alkenylene ring which is unsubstituted or substituted and in which in each case one or more methylene groups may be replaced by a substituent such as oxygen, sulfur, -NH or -N (C 1 -C 4 alkyl);
R3 predstavuje vodík, hydroxylovú skupinu, NH2, NH(CrC4-alkyl), N(CrC4alkyl)2, halogén, CrC4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, Ci-C4-halogénalkyl, CrC4-alkoxy, CrC4-halogénalkoxy, Ci-C4-alkyltio; alebo CR3 je pripojený k CR10 ako je uvedené vyššie, za vzniku 5- alebo 6-členného kruhu;R 3 is H, OH, NH2, NH (Ci-C4 alkyl), N (C r C 4 alkyl) 2, halo, -C 4 -alkyl, C 2 -C 4 -alkenyl, C 2 -C 4 -alkynyl , Ci-C4 haloalkyl, Ci-C4 alkoxy, -C 4 haloalkoxy, Ci-C4-alkylthio; or CR 3 is attached to CR 10 as above to form a 5- or 6-membered ring;
R4 a R5 (ktoré môžu byť rovnaké alebo rozdielne) znamenajú fenyl alebo naftyl, nesubstituovaný alebo substituovaný, alebo fenyl alebo naftyl, ktoré sú viazané spolu v orto-polohách priamou väzbou, metylénovú, etylénovú alebo etenylénovú skupinu, atóm kyslík alebo síry alebo SO2, N H alebo N-alkylovú skupinuR 4 and R 5 (which may be the same or different) denote phenyl or naphthyl, unsubstituted or substituted, or phenyl or naphthyl, which are bonded together in ortho positions by a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or SO 2 , NH or N-alkyl
C3-C8-cykloalkyl, nesubstituovaný alebo substituovaný;C 3 -C 8 cycloalkyl, unsubstituted or substituted;
R6 predstavuje vodík, CrCa-alkyl, C3-Ce-alkenyl alebo C3-Ce-alkinyl, pričom každý z týchto zvyškov môže byť substituovaný jedným alebo viacerými substituentami zvolenými zo skupiny zahrňujúcej halogén, hydroxylovú skupinu, merkaptoskupinu, karboxylovú skupinu, nitroskupinu, aminoskupinu, kyanoskupinu, CrC4-alkoxy, C3-C6-alkenyloxy, C3-C6-alkinyloxy,R 6 is hydrogen, C 1 -C 6 -alkyl, C 3 -C 6 -alkenyl or C 3 -C 6 -alkynyl, each of which may be substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, mercapto, carboxyl, nitro, amino , CN, C r C 4 -alkoxy, C 3 -C 6 alkenyloxy, C 3 -C 6 alkynyloxy,
-4Ci-C4-alkyltio, Ci-C4-halogénalkoxy, Ci-C4-alkylkarbonyl, CrC4-alkoxykarbonyl, C3.e-alkylkarbonylalkyl, NH(Ci-C4-alkyl), N(Ci-C4-alkyl)2, C3-C8cykloalkyl, hetaryloxy alebo hetaryl, päť- alebo šesť-členný, obsahujúci jeden až tri atómy dusíka a/alebo jeden atóm síry alebo kyslíka, fenoxy alebo fenyl, pričom uvedené arylové zvyšky môžu samotné byť substituované jedným alebo viacerými substituentami, napríklad jedným až troma substituentami zvolenými zo skupiny zahrňujúcej halogén, hydroxylovú skupinu, merkaptoskupinu, karboxylovú skupinu, nitroskupinu, kyanoskupinu, Ci-C4-alkyl, CrC4-halogénalkyl, Ci-C4-alkoxy, Cr C4-halogénalkoxy, aminoskupinu, NH(Ci-C4-alkyl), N(C-i-C4-alkyl)2 alebo Ci-C4-alkyltio;-4Ci -C 4 alkylthio, Ci-C4 haloalkoxy, Ci-C4 alkylcarbonyl, -C 4 -alkoxycarbonyl, C3.e-alkylcarbonylalkyl, NH (Ci-C4 alkyl), N (C 4 - alkyl) 2, C 3 -C 8 cycloalkyl, hetaryloxy or hetaryl, five- or six-membered, containing one to three nitrogen atoms and / or one sulfur or oxygen atom, phenoxy or phenyl, wherein said aryl residues may themselves be substituted by one or by multiple substituents, for example one to three substituents selected from the group consisting of halogen, hydroxyl, mercapto, carboxyl, nitro, cyano, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 1 -C 4 -alkoxy, C 1 -C 4 - haloalkoxy, amino, NH (C 1 -C 4 -alkyl), N (C 1 -C 4 -alkyl) 2 or C 1 -C 4 -alkylthio;
fenyl alebo naftyl, z ktorých každý môže byť substituovaný jedným alebo viacerými z nasledujúcich zvyškov, ako je halogén, nitroskupina, kyanoskupina, hydroxylová skupina, amínoskupina, Ci-C4-alkyl, Ci-C4halogénalkyl, CrC4-alkoxy, Ci-C4-halogénalkoxy, fenoxy, Ci-C4-alkyltio, CrC4-alkylamino, Ci-C4-dialkylamino, dioxometylén alebo dioxoetylén;phenyl or naphthyl, each of which may be substituted by one or more of the following radicals such as halogen, nitro, cyano, hydroxyl, amino, C 1 -C 4 -alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkoxy C 4 haloalkoxy, phenoxy, Cl-C4 alkylthio, Ci-C4 alkylamino, Ci-C4-dialkylamino, dioxomethylene or dioxoethylene;
päť- alebo šesť-členný heteroaromatický systém obsahujúci jeden až tri atómy dusíka a/alebo jeden atóm síry alebo kyslíka, ktorý môže niesť jeden až štyri atómy halogénu a/alebo jeden až dva z nasledujúcich zvyškov: CrC4-alkyl, CrC4-halogénalkyl, Ci-C4-alkoxy, CrC4-halogénalkoxy, Ci—C4—alkyltio, fenyl, fenoxy alebo fenylkarbonyl, pričom fenylové zvyšky samotné môže niesť jeden až päť atómov halogénu a/alebo jeden až tri z nasledujúcich zvyškov, ako je Ci—C4—alkyl, Ci-C4-halogénalkyl, Ci-C4-alkoxy, Ci-C4-halogénalkoxy a/alebo C1—C4—alkyltio;a five- or six-membered heteroaromatic system containing one to three nitrogen atoms and / or one sulfur or oxygen atom which may carry one to four halogen atoms and / or one to two of the following: C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl , C 4 -alkoxy, C r C 4 -haloalkoxy, C 4 alkylthio, phenyl, phenoxy or phenylcarbonyl, where the phenyl radicals themselves can carry one to five halogen atoms and / or one to three of the following radicals: it is Ci-C4-alkyl, Ci-C4 haloalkyl, Ci-C4-alkoxy, Ci-C4 -haloalkoxy and / or C1 -C4 -alkylthio;
C3-Ce-cykloalkyl, pričom tieto zvyšky môžu byť substituované jedným alebo viacerými substituentami zvolenými zo skupiny zahrňujúcej halogén, hydroxylovú skupinu, merkaptoskupinu, karboxylovú skupinu, nitroskupinu, kyanoskupinu, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, CiC4-alkoxy, Ci-C4-alkyltio, Ci-C4-halogénalkoxy;C 3 -C 6 -cycloalkyl, which radicals may be substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, mercapto, carboxyl, nitro, cyano, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, C 2 -C 4 -alkenyl C4-alkynyl, Ci-4 alkoxy, Ci-4 alkylthio, Ci-4 haloalkoxy;
Z predstavuje síru alebo kyslík;Z is sulfur or oxygen;
B znamená C2-C4-alkylén;B is C 2 -C 4 -alkylene;
-5Het predstavuje heterocyklický zvyšok vzorca la alebo lb-5Het represents a heterocyclic radical of formula Ia or 1b
la Ib kdela Ib where
T znamená O, S, NR8 T represents O, S, NR 8
R8 predstavuje Ci-C6-alkyl a fyziologicky prijateľné soli a enantiomérne čisté formy.R 8 represents C 1 -C 6 -alkyl and physiologically acceptable salts and enantiomerically pure forms.
V tejto súvislosti a v ďalšom platia nasledujúce definície:In this context and beyond, the following definitions apply:
Alkalickým kovom je napríklad lítium, sodík, draslík;The alkali metal is, for example, lithium, sodium, potassium;
Kovom alkalickej zeminy je napríklad vápnik, horčík, bárium;The alkaline earth metal is, for example, calcium, magnesium, barium;
C3-Ce-cykloalkyom je napríklad cyklopropyl, cyklobutyl, cyklopentyl, cyklohexyl, cykloheptyl alebo cyklooktyl;C 3 -C 6 -cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl;
Ci-C4-halogénalkyl môže byť lineárny alebo rozvetvený, ako je fluórmetyl, difluórmetyl, trifluórmetyl, chlórdifluórmetyl, dichlórfluórmetyl, trichlórmetyl, 1—fluóretyl, 2-fluóretyl, 2,2—difluóretyl, 2,2,2-trifluóretyl, 2—chlór—2,2—difluóretyl, 2,2-dichlór-2fluóretyl, 2,2,2—trichlóretyl alebo pentafluóretyl;C 1 -C 4 -haloalkyl can be linear or branched, such as fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, trichloromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2- chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl or pentafluoroethyl;
C-i-C4-halogénalkoxy môže byť lineárny alebo rozvetvený, ako je difluórmetoxy, trifluórmetoxy, chlórdifluórmetoxy, 1-fluóretoxy, 2,2-difluóretoxy, 1,1,2,2-tetrafIuór-etoxy, 2,2,2-trifluóretoxy, 2—chlór—1,1,2—trifluóretoxy, 2-fluóretoxy alebo pentafluóretoxy;C 1 -C 4 -haloalkoxy may be linear or branched, such as difluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, 1-fluoroethoxy, 2,2-difluoroethoxy, 1,1,2,2-tetrafluoroethoxy, 2,2,2-trifluoroethoxy, 2-fluoroethoxy —Chloro-1,1,2-trifluoroethoxy, 2-fluoroethoxy or pentafluoroethoxy;
Ci-C4-alkyl môže byť lineárny alebo rozvetvený, ako je metyl, etyl, 1-propyl, 2propyl, 2-metyl-2-propyl, 2-metyl-1-propyl, 1-butyl alebo 2—butyl;C 1 -C 4 -alkyl may be linear or branched such as methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-2-propyl, 2-methyl-1-propyl, 1-butyl or 2-butyl;
C2-C4-alkenyl môže byť lineárny alebo rozvetvený, ako je etenyl, 1-propen-3-yl, 1propen-2-yl, 1-propen-1-yl, 2-metyl-1-propenyl, 1-butenyl alebo 2-butenyl;C 2 -C 4 -alkenyl may be linear or branched, such as ethenyl, 1-propen-3-yl, 1-propen-2-yl, 1-propen-1-yl, 2-methyl-1-propenyl, 1-butenyl or 2-butenyl;
C2-C4-alkinyl môže byť lineárny alebo rozvetvený, ako je etinyl, 1—propin—1—yl, 1propin-3-yl, 1 —butin—4—yl alebo 2—butin—4—yl;C 2 -C 4 -alkynyl may be linear or branched such as ethynyl, 1-propyn-1-yl, 1-propin-3-yl, 1-butin-4-yl or 2-butin-4-yl;
-6Ci-C4-alkoxy môže byť lineárny alebo rozvetvený, ako je metoxy, etoxy, propoxy, 1metyletoxy, butoxy, 1-metylpropoxy, 2-metylpropoxy alebo 1,1-dimetyletoxy;-6-C 1 -C 4 -alkoxy may be linear or branched, such as methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1,1-dimethylethoxy;
Ca-Ce-alkenyloxy môže byť lineárny alebo rozvetvený, ako je alyloxy, 2-buten-1yloxy alebo 3-buten-2-yloxy;The C 6 -C 6 -alkenyloxy may be linear or branched, such as allyloxy, 2-buten-1-yloxy or 3-buten-2-yloxy;
C3-C6-alkinyloxy môže byť lineárny alebo rozvetvený, ako je 2-propin- 1-yloxy, 2butin-1-yloxy alebo 3-butin-2-yloxy;C3-C6-alkynyloxy may be linear or branched, such as 2-propyn-1-yloxy, 2-butin-1-yloxy or 3-butin-2-yloxy;
Ci-C4-alkyltio môže byť lineárny alebo rozvetvený, ako je metyltio, etyltio, propyltio, 1—metyletyltio, butyltio, 1-metylpropyltio, 2-metylpropyltio alebo 1,1—dimetyletyltio;C 1 -C 4 -alkylthio may be linear or branched such as methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio or 1,1-dimethylethylthio;
Ci-C4-alkylkarbonyl môže byť lineárny alebo rozvetvený, ako je acetyl, etylkarbonyl alebo 2-propylkarbonyl;C 1 -C 4 -alkylcarbonyl may be linear or branched, such as acetyl, ethylcarbonyl or 2-propylcarbonyl;
Ci-C4-alkoxykarbonyl môže byť lineárny alebo rozvetvený, ako je metoxykarbonyl, etoxykarbonyl, n-propoxykarbonyl, i-propoxykarbonyl alebo n-butoxykarbonyl;C 1 -C 4 -alkoxycarbonyl may be linear or branched, such as methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, i-propoxycarbonyl or n-butoxycarbonyl;
C3-Ce-alkylkarbonylalkyl môže byť lineárny alebo rozvetvený, napríklad 2-oxo-1propyl, 3-oxo-1-butyl alebo 3-oxo-2-butylC 3 -C 6 -alkylcarbonylalkyl may be linear or branched, for example 2-oxo-1-propyl, 3-oxo-1-butyl or 3-oxo-2-butyl
Ci-C8-alkyl môže byť lineárny alebo rozvetvený, ako je Ci-C4-alkyl, pentyl, hexyl, heptyl alebo oktyl;C 1 -C 8 -alkyl may be linear or branched, such as C 1 -C 4 -alkyl, pentyl, hexyl, heptyl or octyl;
Halogénom je napríklad fluór, chlór, bróm, jód.Halogen is, for example, fluorine, chlorine, bromine, iodine.
Vynález sa ďalej týka zlúčenín, z ktorých sa môžu uvoľňovať zlúčeniny vzorca I (takzvané prekurzory).The invention further relates to compounds from which compounds of formula I (so-called precursors) can be released.
Výhodnými prekurzormi sú tie prekurzory, pri ktorých sa uvoľňovanie uskutočňuje pri podmienkach podobných tým, ktoré prevládajú v určitých oddeleniach tela, napríklad v žalúdku, črevách krvnom riečišti, pečeni.Preferred precursors are those in which release occurs under conditions similar to those prevalent in certain body compartments, such as the stomach, intestines of the bloodstream, liver.
Zlúčeniny a medziprodukty na ich prípravu, ako sú II, III a IV, môžu obsahovať jeden alebo viac asymetricky substituovaných atómov uhlíka. Zlúčeniny tohto typu môžu jestvovať ako čisté enantioméry alebo čisté diastereoizoméry alebo ako ich zmesi Výhodné je použitie enantiomérne čistých zlúčenín ako účinnej zložky.The compounds and intermediates for their preparation, such as II, III and IV, may contain one or more asymmetrically substituted carbon atoms. Compounds of this type may exist as pure enantiomers or pure diastereoisomers or as mixtures thereof. The use of enantiomerically pure compounds as an active ingredient is preferred.
-7Vynález sa ďalej týka použitia vyššie uvedených derivátov karboxylových kyselín na prípravu liečiv, predovšetkým prípravu inhibítorov ETA a ETb receptorov. Zlúčeniny podľa vynálezu sú predovšetkým vhodné ako zmesné antagonisty, ako definované v úvode.The invention further relates to the use of the aforementioned carboxylic acid derivatives for the preparation of medicaments, in particular the preparation of inhibitors of ET A and ETb receptors. The compounds of the invention are particularly useful as mixed antagonists as defined in the introduction.
Zlúčeniny vzorca IV, v ktorom Z znamená síru alebo kyslík, sa môžu pripraviť tiež v enantiomérne čistej forme, ako je opísané vo WO 96/11914.Compounds of formula IV in which Z is sulfur or oxygen can also be prepared in enantiomerically pure form as described in WO 96/11914.
Zlúčeniny vzorca III sú buď známe alebo sa môžu syntetizovať napríklad redukciou zodpovedajúcich karboxylových kyselín alebo ich esterov, alebo pomocou iných všeobecne známych spôsobov.Compounds of formula III are either known or can be synthesized, for example, by reduction of the corresponding carboxylic acids or esters thereof, or by other generally known methods.
Zlúčeniny podľa vynálezu, kde substituenty majú významy definované pri vzorci I, sa môžu pripraviť napríklad reakciou derivátov karboxylových kyselín vzorca IV, kde substituenty majú uvedený význam, so zlúčeninami vzorca V.The compounds of the invention wherein the substituents have the meanings defined in formula I may be prepared, for example, by reacting the carboxylic acid derivatives of formula IV, where the substituents are as defined above, with the compounds of formula V.
IV + R11 - Het v 11 + H 11
R11 vo vzorci V znamená halogén alebo R12-SO2-, kde R12 môže predstavovať CrC4-alkyl, Ci-C4-halogénalkyl alebo fenyl. Okrem toho, najmenej jeden z členov kruhu X alebo Y alebo Z znamená dusík. Reakcia sa výhodne uskutočňuje v inertnom rozpúšťadle alebo riedidle s prídavkom vhodnej zásady, t.j. zásady, ktorá deprotonuje medziprodukt IV, pri teplote v rozsahu od laboratórnej teploty po teplotu varu rozpúšťadla.R 11 in formula V is halogen or R 12 -SO 2 -, wherein R 12 can be C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl or phenyl. In addition, at least one of the ring members X or Y or Z is nitrogen. The reaction is preferably carried out in an inert solvent or diluent with the addition of a suitable base, i.e. a base which deprotonates intermediate IV, at a temperature ranging from room temperature to the boiling point of the solvent.
Zlúčeniny typu I, kde R = COOH sa môžu okrem toho získať priamo, keď sa medziprodukt IV, v ktorom R znamená COOH deprotonuje s dvoma ekvivalentami vhodnej zásady a nechá sa reagovať so zlúčeninami vzorca V. Táto reakcia saCompounds of type I wherein R = COOH can additionally be obtained directly when intermediate IV, wherein R is COOH, is deprotonated with two equivalents of a suitable base and reacted with compounds of formula V.
-8taktiež uskutočňuje v inertnom rozpúšťadle a pri teplote v rozsahu od laboratórnej teploty po teplotu varu rozpúšťadla.It is also carried out in an inert solvent and at a temperature ranging from room temperature to the boiling point of the solvent.
Príkladmi takýchto rozpúšťadiel a riedidiel sú alifatické, alicyklické a aromatické uhľovodíky, z ktorých každý môže byť chlórovaný, ako je hexán, cyklohexán, petroléter, nafta, benzén, toluén, xylén, metylénchlorid, chloroform, tetrachlorid uhličitý, etylchlorid and trichlóretylén, étery, ako je diizopropyléter, dibutyléter, metylterc-butyléter, propylénoxid, dioxán a tetrahydrofurán, nitrily, ako je acetonitril a propionitril, amidy, ako je dimetylformamid, dimetylacetamid a N-metylpyrolidón, sulfoxidy a sulfóny, ako je dimetylsulfoxid a sulfolán.Examples of such solvents and diluents are aliphatic, alicyclic and aromatic hydrocarbons, each of which may be chlorinated, such as hexane, cyclohexane, petroleum ether, naphtha, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethyl chloride and trichlorethylene, ethers, ethers, ethers, ethers, ethers, ethers, is diisopropyl ether, dibutyl ether, methyl tert-butyl ether, propylene oxide, dioxane and tetrahydrofuran, nitriles such as acetonitrile and propionitrile, amides such as dimethylformamide, dimethylacetamide and N-methylpyrrolidone, sulfoxides and sulfones such as dimethylsulfoxide and sulfolane.
Zlúčeniny vzorca V sú známe alebo sa, v niektorých prípadoch, môžu zakúpiť alebo pripraviť s použitím všeobecne známych postupov.Compounds of formula V are known or, in some cases, can be purchased or prepared using generally known procedures.
Ako zásada sa môže použiť hydrid alkalického kovu alebo kovu alkalickej zeminy, ako je hydrid sodný, hydrid draselný alebo hydrid vápenatý, uhličitan, ako je uhličitan alkalického kovu, napríklad uhličitan sodný alebo draselný, hydroxid alkalického kovu alebo kovu alkalickej zeminy, ako je hydroxid sodný alebo draselný, organokovová zlúčenina, ako je butyllítium alebo amid alkalického kovu, ako je diizopropylamid lítia alebo amid lítia.As the base, an alkali metal or alkaline earth metal hydride such as sodium hydride, potassium hydride or calcium hydride, a carbonate such as an alkali metal carbonate such as sodium or potassium carbonate, an alkali metal or an alkaline earth metal hydroxide such as sodium hydroxide can be used. or a potassium, organometallic compound such as butyllithium or an alkali metal amide such as lithium diisopropylamide or lithium amide.
Zlúčeniny vzorca I sa môžu tiež pripraviť tak, že sa vychádza zo zodpovedajúcich karboxylových kyselín, t.j. zlúčenín vzorca I, kde R1 znamená COOH, a tieto sa konvergujú najskôr bežným spôsobom na aktivovanú formu, ako je halogenid, anhydrid alebo imidazolid kyseliny, a táto forma sa potom nechá reagovať s vhodnou hydroxylovou zlúčeninou HOR7. Táto reakcia sa môže uskutočňovať vo bežných rozpúšťadlách a často sa vyžaduje pridanie zásady, pričom v takomto prípade vhodnými sú vyššie uvedené zásady. Tieto dva kroky sa môžu napríklad zjednodušiť tak, že sa karboxylová kyselina nechá pôsobiť na hydroxylovú zlúčeninu v prítomnosti dehydratačného činidla, ako je karbodiimid.Compounds of formula I may also be prepared starting from the corresponding carboxylic acids, i.e., compounds of formula I wherein R 1 is COOH, and these are first converted in the conventional manner to an activated form, such as an acid halide, anhydride or imidazolide, and the form is then reacted with a suitable hydroxyl compound HOR 7 . This reaction can be carried out in conventional solvents and the addition of a base is often required, in which case the abovementioned bases are suitable. For example, these two steps can be simplified by treating the hydroxyl compound with a carboxylic acid in the presence of a dehydrating agent such as carbodiimide.
Ďalej sa tiež môžu zlúčeniny vzorca I pripraviť tak, že sa vychádza zo solí vhodných karboxylových kyselín, t.j. zo zlúčenín vzorca I, kde R1 znamená skupinuFurthermore, the compounds of formula I may also be prepared starting from salts of suitable carboxylic acids, i.e. compounds of formula I, wherein R 1 represents a group
COR a R predstavuje OM, pričom M môže znamenať katión alkalického kovu alebo ekvivalent katiónu kovu alkalickej zeminy. Tieto soli môžu reagovať s mnohými zlúčeninami vzorca R-A, kde A znamená konvenčnú nukleofúgnu odstupujúcuCOR and R are OM, where M may be an alkali metal cation or an equivalent of an alkaline earth metal cation. These salts can be reacted with a number of compounds of formula R-A, wherein A is a conventional nucleophage leaving
-9skupinu, napríklad halogén, ako je chlór, bróm, jód alebo nesubstituovaný alebo halogén-, alkyl- alebo halogénalkyl-substituovaný aryl alebo alkylsulfonyl, ako je toluénsulfonyl a metylsulfonyl, alebo ďalšia ekvivalentná odstupujúca skupina. Zlúčeniny vzorca R-A s reaktívnym substituentom A sú známe alebo sa ľahko získať s použitím všeobecných poznatkov známych pre odborníkov v odbore. Táto reakcia sa môže uskutočňovať v bežných rozpúšťadlách a výhodne sa uskutočňuje s pridaním zásady, pričom v takomto prípade sú vhodné vyššie uvedené zásady.A group such as halogen, such as chlorine, bromine, iodine or unsubstituted or halogen-, alkyl- or haloalkyl-substituted aryl or alkylsulfonyl, such as toluenesulfonyl and methylsulfonyl, or another equivalent leaving group. Compounds of formula R-A with a reactive substituent A are known or readily obtained using general knowledge known to those skilled in the art. This reaction may be carried out in conventional solvents and preferably carried out with the addition of a base, in which case the abovementioned bases are suitable.
Z hľadiska biologického účinku, výhodnými derivátmi karboxylových kyselín vzorca I, a to ako čisté enantioméry tak i čisté diastereoizoméry a ich zmesi, sú tie, v ktorých substituenty majú nasledujúce významy:In terms of biological activity, preferred carboxylic acid derivatives of formula I, both pure enantiomers and pure diastereoisomers and mixtures thereof, are those in which the substituents have the following meanings:
R1 znamená COOR7, v ktoromR 1 is COOR 7 wherein
R7 predstavuje vodík, katión alkalického kovu, katión kovu alkalickej zeminy alebo fyziologicky prijateľný organický amóniový ión;R 7 represents hydrogen, an alkali metal cation, an alkaline earth metal cation or a physiologically acceptable organic ammonium ion;
Ca-Ce-cykloalkyl, Ci-Ce-alkyl;C 6 -C 6 -cycloalkyl, C 1 -C 6 -alkyl;
CH2-fenyl, nesubstituovaný alebo substituovaný;CH 2 -phenyl, unsubstituted or substituted;
C3-C6-alkenylovú alebo C3-O6-alkinylovú skupinu, nesubstituovanú alebo substituovanú; alebo fenyl, nesubstituovaný alebo substituovaný.C 3 -C 6 alkenyl or C 3 -O6-alkynyl, unsubstituted or substituted; or phenyl, unsubstituted or substituted.
R2 znamená vodík, hydroxylovú skupinu, halogén, N(Ci-C4-alkyl)2, CrCralkyl, Ci-C4-alkoxy, Ci—C4—alkyltio, Ci-C4-halogénalkyl, Ci-C4-halogénalkoxy alebo CR2 je viazaný k CR10, ako je uvedené nižšie, za vzniku 5- alebo 6členného kruhu, alebo, ak Het znamená päťčlenný kruh, CR2 môže spolu s CR3 predstavovať 5- alebo 6-členný alkenyl alebo alkylenylový kruh, ktorý je nesubstituovaný alebo substituovaný;R 2 is H, OH, halogen, N (Cl-4 alkyl) 2, CrCralkyl, Ci-C4-alkoxy, Ci-C4-alkylthio, Ci-C4-haloalkyl, Ci-C4-haloalkoxy, or CR2 is bonded to CR 10 as shown below to form a 5- or 6-membered ring, or, when Het is a five-membered ring, CR 2 may together with CR 3 represent a 5- or 6-membered alkenyl or alkylenyl ring that is unsubstituted or substituted ;
X predstavuje dusík alebo metín;X represents nitrogen or methine;
Y znamená dusík alebo metín;Y is nitrogen or methine;
W predstavuje dusík alebo CR10, kde R10 znamená vodík alebo Ci^-alkyl, alebo CR10 tvorí spolu s CR2 alebo CR3 5- alebo 6-členný alkylénový alebo alkenylénový kruh, ktorý môže byť substituovaný jednou alebo dvomi metylovými skupinami a v ktorom v každom prípade metylénováW represents nitrogen or CR 10 , wherein R 10 represents hydrogen or C 1-6 -alkyl, or CR 10 together with CR 2 or CR 3 forms a 5- or 6-membered alkylene or alkenylene ring which may be substituted with one or two methyl groups and which in any case is methylene
-10skupina môže byť nahradená kyslíkom alebo sírou, ako je -CH2-CH2-O-, -CH2-CH2-CH2-O-, -CH=CH-O-, -CH=CH-CH2O-, -CH(CH3)-CH(CH3)0-, -CH=C(CH3)-O-, -C(CH3)=C(CH3)-O-, alebo -C(CH3)=C(CH3)-S; napokon, jeden z členov kruhu X, Y alebo W znamená dusík.The -10 group can be replaced by oxygen or sulfur, such as -CH 2 -CH 2 -O-, -CH 2 -CH 2 -CH 2 -O-, -CH = CH-O-, -CH = CH-CH 2 O-, -CH ( CH 3 ) -CH (CH 3 ) 0 -, -CH = C (CH 3 ) -O-, -C (CH 3 ) = C (CH 3 ) -O-, or -C (CH 3 ) = C ( CH 3) -S; finally, one of the ring members X, Y or W is nitrogen.
R3 znamená vodík, hydroxylovú skupinu, halogén, N(CrC4-alkyl)2, C1-C4—alkyl,R 3 is hydrogen, hydroxyl, halogen, N (C 1 -C 4 -alkyl) 2 , C 1 -C 4 -alkyl,
Ci-C4-alkoxy, C1-C4-alkyltio, Ci-C4-halogénalkyl, Ci-C4-halogénalkoxy, alebo CR3 je viazaný k CR10, ako je uvedené vyššie, za vzniku 5- alebo 6-členného kruhu, alebo, ak Het znamená päťčlenný kruh, CR2 môže spolu s CR3 predstavovať 5- alebo 6-členný alkenylový alebo alkylenylový kruh, ktorý je nesubstituovaný alebo substituovaný;C 1 -C 4 -alkoxy, C 1 -C 4 -alkylthio, C 1 -C 4 -haloalkyl, C 1 -C 4 -haloalkoxy, or CR 3 is attached to CR 10 as above to form a 5- or 6-membered ring, or, when Het represents a five membered ring, CR 2 together with CR 3 may represent a 5- or 6-membered alkenyl or alkylenyl ring which is unsubstituted or substituted;
R4 a R5 (ktoré môžu byť rovnaké alebo rozdielne) predstavujú:R 4 and R 5 (which may be the same or different) represent:
fenyl alebo naftyl, z ktorých každý môže byť substituovaný jedným alebo viacerými z nasledujúcich zvyškov, ako je halogén, nitroskupina, kyanoskupina, hydroxylová skupina, merkaptoskupina, aminoskupina, C-iC4-alkyl, Ci-C4-halogénalkyl, CrC4-alkoxy, Ci-C4-halogénalkoxy, fenoxy, CrC4-alkyltio, NH(Ci-C4-alkyl) alebo N(Ci-C4-alkyl)2 alebo fenyl, ktorý môže byť substituovaný jedenkrát alebo viackrát, napríklad jedenkrát až trikrát substituentom zvoleným zo skupiny zahrňujúcej halogén, nitroskupinu, kyanoskupinu, Ci-C4r-alkyl, Ci-C4-halogénalkyl, Ci-C4-alkoxy, C1-C4-halogénalkoxy alebo Cľ-C^-alkyltio; alebo fenyl alebo naftyl, ktoré sú spolu pripojené vorto polohách priamou väzbou, metylénovú, etylénovú alebo etenylénovú skupinu, atóm kyslíka alebo síry alebo skupinu S02, NH alebo N-alkylovú skupinu; C3-Ce-cykloalkyl;phenyl or naphthyl, each of which may be substituted with one or more of the following radicals such as halogen, nitro, cyano, hydroxyl, mercapto, amino, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 1 -C 4 -alkoxy , C 4 haloalkoxy, phenoxy, C4-alkylthio, NH (Ci-C4 alkyl) or N (Ci-C 4 -alkyl) 2 or phenyl which may be substituted one or more times, for example one to three substituents selected from halogen, nitro, cyano, C C4R-alkyl, Ci-C4 haloalkyl, Ci-C 4 -alkoxy, C 1 -C 4 -haloalkoxy or C-C ^ alkylthio; or phenyl or naphthyl which are connected together in the ortho positions by a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or a group S0 2, NH or N-alkyl; C 3 -C 6 -cycloalkyl;
R6 znamená C3-Ce-cykloalkyl, pričom tieto zvyšky môžu byť substituované jedenkrát alebo viackrát substituentom zvoleným zo skupiny zahrňujúcej halogén, hydroxylovú skupinu, merkaptoskupinu, karboxylovú skupinu, nitroskupinu, kyanoskupinu, C1-C4-alkoxy, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, Cr-Ce-alkenyloxy, C3-C6-alkinyloxy, Ci-C4-alkyltio, C1C4-halogénalkoxy, Ci-C4-alkylkarbonyl, Ci-C4-alkoxykarbonyl, NH(CiC4“alkyl), N(Ci-C4-alkyl)2 alebo fenyl, ktorý môže byť substituovanýR 6 represents C 3 -C 6 -cycloalkyl, which residues may be substituted one or more times with a substituent selected from the group consisting of halogen, hydroxyl, mercapto, carboxyl, nitro, cyano, C 1 -C 4 -alkoxy, C 1 -C 4 -alkyl , C 2 -C 4 -alkenyl, C 2 -C 4 -alkynyl, Cr-Ce-alkenyloxy, C3-C6-alkynyloxy, Ci-C 4 alkylthio, C1C 4 -haloalkoxy, C 4 -alkylcarbonyl, C 4 -alkoxycarbonyl, NH (C 1 -C 4 alkyl), N (C 1 -C 4 alkyl) 2 or phenyl which may be substituted
-11 jedenkrát alebo viackrát, napríklad jedenkrát až trikrát substituentom zvoleným zo skupiny zahrňujúcej halogén, nitroskupinu, kyanoskupinu, Ci-C4-alkyl, Ci-C4-halogénalkyl, Ci-C4-alkoxy, Ci-C4-halogénalkoxy alebo Ci-C4-alkyltio;-11 once or more, e.g. one to three times by a substituent selected from halogen, nitro, cyano, Ci-C4-alkyl, Ci-C4 haloalkyl, Ci-C4-alkoxy, Ci-C 4 -haloalkoxy or C-C 4- alkylthio;
fenyl alebo naftyl, z ktorých každý môže byť substituovaný jedným alebo viacerými z nasledujúcich zvyškov, ako je halogén, nitroskupina, merkaptoskupina, karboxylová skupina, kyanoskupina, hydroxylová skupina, aminoskupina, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, C3C6-alkenyloxy, C^-CU-halogénalkyl, C3-C6-alkinyloxy, Ci—C4—alkylkarbonyl, ^-^-alkoxykarbonyl, Ci-C4-alkoxy, Ci-C4-halogénalkoxy, fenoxy, C1—C4—alkyltio, NH(Ci-C4-alkyl), N(Ci-C4-alkyl)2, dioxometylén, dioxoetylén alebo fenyl, ktorý môže byť substituovaný jedenkrát alebo viackrát, napríklad jedenkrát až trikrát substituentom zvoleným zo skupiny zahrňujúcej halogén, nitroskupinu, kyanoskupinu, Ci-C4-alkyl, C1-C4halogénalkyl, Ci-C4-alkoxy, Ci-C4-halogénalkoxy alebo C1-C4-alkyltio;phenyl or naphthyl, each of which may be substituted with one or more of the following radicals such as halogen, nitro, mercapto, carboxyl, cyano, hydroxyl, amino, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, C 2 -C 4 -alkynyl, C 3 -C 6 -alkenyloxy, C 1 -C 4 -haloalkyl, C 3 -C 6 -alkynyloxy, C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl, C 1 -C 4 -alkoxy, C 1 -C 4 -haloalkoxy , phenoxy, C 1 -C 4 alkylthio, NH (Cl-4 alkyl), N (Ci-C4 alkyl) 2, dioxomethylene, dioxoethylene or phenyl, which is optionally substituted one or more times, for example one to three times by a substituent selected from halogen, nitro, cyano, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -haloalkoxy or C 1 -C 4 -alkylthio;
päť- alebo šesťčlenný heteroaromatický systém obsahujúci jeden až tri atómy dusíka a/alebo jeden atóm síry alebo kyslíka, ktorý môže niesť jeden až štyri atómy halogénu a/alebo jeden až dva z nasledujúcich zvyškov, ako je C1-C4-alkyl, C1-C4-halogénalkyl, C1-C4-alkoxy, C1-C4halogénalkoxy, Ci-C4-alkyltio, fenyl, fenoxy alebo fenylkarbonyl, pričom samotné fenylové zvyšky môžu niesť jeden až päť atómov halogénu a/alebo jeden až tri z nasledujúcich zvyškov, ako je Ci-C4-alkyl, C1-C4halogénalkyl, Ci-C4-alkoxy, Ci-C4-halogénalkoxy a/alebo C1-C4-alkyltio;a five- or six-membered heteroaromatic system containing one to three nitrogen atoms and / or one sulfur or oxygen atom which may carry one to four halogen atoms and / or one to two of the following radicals, such as C 1 -C 4 -alkyl, C 1 - C 4 -haloalkyl, C 1 -C 4 -alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 -alkylthio, phenyl, phenoxy or phenylcarbonyl, the phenyl radicals alone may carry one to five halogen atoms and / or one to three of the following radicals, such as Ci-C4 alkyl, C1-C4 haloalkyl, Ci-C4-alkoxy, Ci-C4 -haloalkoxy and / or C1 -C4 -alkylthio;
Z predstavuje síru alebo kyslík;Z is sulfur or oxygen;
B znamená C2-C4-alkylén;B is C 2 -C 4 -alkylene;
Het predstavuje heterocyklickú skupinu vzorca la alebo lb, kde T = 0, S.Het represents a heterocyclic group of formula Ia or 1b, wherein T = O, S.
Predovšetkým výhodnými zlúčeninami vzorca I, ako čisté enantioméry tak aj čisté diastereoizoméry a ich zmesi, sú tie, v ktorých substituenty majú nasledujúce významy:Particularly preferred compounds of formula I, both pure enantiomers and pure diastereoisomers and mixtures thereof, are those wherein the substituents have the following meanings:
R’ znamená COOH;R 'means COOH;
-12X, Y predstavujú N;-12X, Y represent N;
W znamená CR10;W is CR 10 ;
R2, R3 predstavujú vodík, hydroxylovú skupinu, NH2, NH(Ci-C4-alkyl), N(CrC4alkyl)2, halogén, Ci-C4-alkyl, C2-C4-alkenyl1 C2-C4-alkinyl, Ci-C4-halogénalkyl, CrC4-alkoxy, Ci-C4-halogénalkoxy alebo CrC4-alkyltio, alebo CR2 je viazaný k CR10, ako je uvedené nižšie, za vzniku 5- alebo 6-členného kruhu, alebo, ak Het znamená päťčlenný kruh, CR2 môže spolu s CR3 predstavovať 5- alebo 6-členný alkylénový alebo alkylenylový kruh, ktorý je nesubstituovaný alebo substituovaný;R 2, R 3 are hydrogen, hydroxyl, NH2, NH (Ci-4 alkyl), N (C r C4 alkyl) 2, halo, C 4 alkyl, C 2 -C 4 -alkenyl C 1 2 C4-alkynyl, Ci-C 4 haloalkyl, C r C 4 alkoxy, C 4 -haloalkoxy or C r C 4 alkylthio, or CR2 is linked to CR10 as indicated below to give a 5- or A 6-membered ring, or, when Het represents a five-membered ring, CR 2 may together with CR 3 represent a 5- or 6-membered alkylene or alkylenyl ring which is unsubstituted or substituted;
R4 znamená fenyl, ktorý môže byť substituovaný jedným alebo viacerými z nasledujúcich zvyškov, ako je halogén, nitroskupina, kyanoskupina, hydroxylová skupina, merkaptoskupina, aminoskupina, C1-C4-alkyl, Ci~ C4-halogénalkyl, Ci-C4-alkoxy, Ci-C4-halogénalkoxy, fenoxy, C1-C4alkyltio, NH(Ci-C4-alkyl) alebo N(Ci-C4-alkyl)2 alebo fenyl, ktorý môže byť substituovaný jedenkrát alebo viackrát, napríklad jedenkrát až trikrát, substituentom zvoleným zo skupiny zahrňujúcej halogén, nitroskupinu, kyanoskupinu, Ci-C4-alkyl, Ci-C4-halogénalkyl, Ci-C4-alkoxy, C1-C4halogénalkoxy alebo C1-C4-alkyltio; aleboR 4 represents phenyl, which may be substituted by one or more of the following radicals such as halogen, nitro, cyano, hydroxyl, mercapto, amino, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 1 -C 4 - alkoxy, C 1 -C 4 -haloalkoxy, phenoxy, C 1 -C 4 alkylthio, NH (C 1 -C 4 -alkyl) or N (C 1 -C 4 -alkyl) 2 or phenyl, which may be substituted one or more times, for example one to three times, by a substituent selected from halogen, nitro, cyano, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4 alkoxy, C1 -C4 -haloalkoxy or C 1 -C 4 alkylthio; or
R5 predstavuje fenyl alebo 3,4-dimetoxyfenylR 5 represents phenyl or 3,4-dimethoxyphenyl
R6 znamená Cs-Cr-cykloalkyl, pričom tieto zvyšky môžu byť v každom prípade substituované jedenkrát alebo viackrát substituentom zvoleným zo skupiny zahrňujúcej Ci-C4-alkoxy, Ci-C<-alkyl, C1-C4-alkyltio, halogén, hydroxylovú skupinu, karboxylovú skupinu, kyanoskupinu, trifluórmetylovú skupinu, acetyl alebo fenyl, ktorý môže byť substituovaný jedenkrát alebo viackrát, napríklad jedenkrát až trikrát substituentom zvoleným zo skupiny zahrňujúcej halogén, kyanoskupinu, Ci-C4-alkyl, Ci-C4-halogénalkyl, C1-C4-alkoxy, C1-C4-halogénalkoxy alebo C1-C4-alkyltio;R 6 is C 5 -C 6 -cycloalkyl, which radicals may in each case be substituted one or more times with a substituent selected from the group consisting of C 1 -C 4 -alkoxy, C 1 -C 4 -alkyl, C 1 -C 4 -alkylthio, halogen, hydroxyl , carboxy, cyano, trifluoromethyl, acetyl, or phenyl which can be substituted one or more times, e.g. one to three times by a substituent selected from halogen, cyano, C, -C4 alkyl, C, -C4-haloalkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -haloalkoxy or C 1 -C 4 -alkylthio;
fenyl alebo naftyl, z ktorých každý môže byť substituovaný jedným alebo viacerými z nasledujúcich zvyškov, ako je halogén, nitroskupina, merkaptoskupina, karboxylová skupina, kyanoskupina, hydroxylová skupina, aminoskupina, C1—C4—alkyl, Ci-C4-halogénalkyl, acetyl, (^-04-13alkoxykarbonyl, Ci-C4-alkoxy, C-i-C4-halogénalkoxy, fenoxy, Ci-C4alkyltio, NH(Ci-C4-alkyl), N(Ci—C4—alkyl)2, dioxometylén, dioxoetylén alebo fenyl, ktorý môže byť substituovaný jedenkrát alebo viackrát, napríklad jedenkrát až trikrát substituentom zvoleným zo skupiny zahrňujúcej halogén, nitroskupinu, kyanoskupinu, Ci-C4-alkyl, C-i-C4halogénalkyl, Ci-C4-alkoxy, Ci-C4-halogénalkoxy alebo C-i-C4-alkyltio;phenyl or naphthyl, each of which may be substituted with one or more of the following radicals such as halogen, nitro, mercapto, carboxyl, cyano, hydroxyl, amino, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, acetyl, (C 1-4 -alkoxycarbonyl, C 1 -C 4 -alkoxy, C 1 -C 4 -haloalkoxy, phenoxy, C 1 -C 4 alkylthio, NH (C 1 -C 4 -alkyl), N (C 1 -C 4 -alkyl) 2 , dioxomethylene, dioxoethylene or phenyl, which may be substituted one or more times, for example one to three times with a substituent selected from the group consisting of halogen, nitro, cyano, C 1 -C 4 -alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 -alkoxy, C 1 -C 4 - haloalkoxy or C 1 -C 4 -alkylthio;
päť- alebo šesťčlenný heteroaromatický systém obsahujúci jeden až tri atómy dusíka a/alebo jeden atóm síry alebo kyslíka, ktorý môže niesť jeden až štyri atómy halogénu a/alebo jeden až dva z nasledujúcich zvyškov, ako je C4—alkyl, Ci-C4-halogénalkyl, Ci-C4-alkoxy, trifluórmetoxy, Ci—C4—alkyltio, fenyl alebo fenoxy, pričom samotné fenylové zvyšky môžu niesť jeden až päť atómov halogénu a/alebo jeden až tri z nasledujúcich zvyškov, ako je Ci-Cr-alkyl, Ci-C4-halogénalkyl, C1-C4alkoxy, C-i-C4-halogénalkoxy a/alebo Ci—C4—alkyltio;a five- or six-membered heteroaromatic system containing one to three nitrogen atoms and / or one sulfur or oxygen atom which may carry one to four halogen atoms and / or one to two of the following radicals, such as C 4 -alkyl, C 1 -C 4 -haloalkyl, C 1 -C 4 -alkoxy, trifluoromethoxy, C 1 -C 4 -alkylthio, phenyl or phenoxy, wherein the phenyl radicals alone may carry one to five halogen atoms and / or one to three of the following radicals, such as C 1 -C 4 - alkyl, Ci-4 haloalkyl, C 1 -C 4 alkoxy, -C 4 -haloalkoxy and / or Ci-4 alkylthio;
Z znamená síru alebo kyslík;Z is sulfur or oxygen;
B predstavuje C3-alkylén;B represents C 3 -alkylene;
Het znamená la, kde R2 a R3 predstavujú metyl a T = O, S.Het is Ia, wherein R 2 and R 3 are methyl and T = O, S.
Zlúčeniny podľa predloženého vynálezu poskytujú nový terapeutický potenciál na liečenie hypertenzie, pulmonálnej hypertenzie, infarktu myokardu, angíny pectoris, akútneho/chronického zlyhania obličiek, renálnej insuficiencie, cerebrálneho vazospazmu, cerebrálnej ischémie, subarachnoidálnych hemorágií, migrény, astmy, aterosklerózy, endotoxického šoku, endotoxínom vyvolaného zlyhania orgánu, intravaskulárnej koagulácie, restenózy po angioplastii, benígnej hypoplázie prostaty, ischemický a intoxikáciou vyvolaného zlyhania obličiek a hypotenzie, metastáz a rastu mezenchymánych tumorov, zlyhania obličiek vyvolaného kontrastnými činidlami, pankreatitídy, gastrointestinálnych vredov.The compounds of the present invention provide novel therapeutic potential for the treatment of hypertension, pulmonary hypertension, myocardial infarction, angina pectoris, acute / chronic renal failure, renal insufficiency, cerebral vasospasm, cerebral ischemia, subarachnoid haemorrhages, endotoxic, asthma, asthma, asthma, asthma organ failure, intravascular coagulation, angioplasty restenosis, benign prostatic hypoplasia, ischemic and intoxication-induced renal failure and hypotension, mesenchymal tumor metastasis and growth, contrast-induced renal failure, pancreatitis, gastrointestinal tract.
Vynález sa ďalej týka kombinovaných prípravkov obsahujúcich antagonisty endotelínového receptora vzorca I a inhibítory renín-angiotenzínového systému. Inhibítormi renín-angiotenzínového systému sú inhibítory reninu, antagonisty angiotenzínu II a predovšetkým inhibítory angiotenzín konvertujúceho enzýmu(ACE).The invention further relates to combination preparations comprising endothelin receptor antagonists of formula I and inhibitors of the renin-angiotensin system. Inhibitors of the renin-angiotensin system are renin inhibitors, angiotensin II antagonists, and in particular angiotensin converting enzyme (ACE) inhibitors.
-14Tieto kombinované prípravky sú predovšetkým vhodné na liečenie a prevenciu hypertenzie a jej následkov a na liečenie srdcového zlyhania.These combination preparations are particularly suitable for the treatment and prevention of hypertension and its sequelae and for the treatment of heart failure.
Dobrý účinok zlúčenín sa môže demonštrovať v nasledujúcich testoch:The good effect of the compounds can be demonstrated in the following tests:
Štúdie väzby receptoraReceptor Binding Studies
Na štúdie väzbovosti sa použili klonované ľudské ETA alebo ETB receptorexprimujúce CHO bunky.Cloned human ET A or ET B receptor expressing CHO cells were used for binding studies.
Príprava membrányPreparation of membrane
ETa alebo ETb receptor-exprimujúce CHO bunky sa nechali rásť v DMEM NUT MIX F12 médiu (Gibco, No. 21331-020) s 10 % fetálneho teľacieho séra (PAA Laboratories GmbH, Linz, No. A15-022), 1 mM glutamínu (Gibco No. 25030-024), 100 U/ml penicilínu and 100 pg/ml streptomycínu (Gibco, Sigma No. P—0781). Po 48 hodinách sa bunky premyli s PBS a inkubovali sa s 0.05 % trypsín-obsahujúceho PBS pri teplote 37 °C počas 5 minút. Potom nasledovala neutralizácia s médiom a zachytenie buniek pomocou centrifúgovania pri 300 x g.ETA or ETB receptor-expressing CHO cells were grown in DMEM NUT MIX F 12 medium (Gibco, No. 21331-020) with 10% fetal calf serum (PAA Laboratories GmbH, Linz, No. A15-022), 1 mM glutamine (Gibco No. 25030-024), 100 U / ml penicillin and 100 µg / ml streptomycin (Gibco, Sigma No. P-0781). After 48 hours, cells were washed with PBS and incubated with 0.05% trypsin-containing PBS at 37 ° C for 5 minutes. This was followed by neutralization with medium and cell capture by centrifugation at 300 x g.
Na prípravu membrány sa bunky upravili na koncentráciu 108 buniek/ml pufra (50 mM tris'HCI pufer, pH 7,4) a potom sa dezintegrovali pomocou ultrazvuku (Branson Sonifier 250,40 až 70 sekúnd/konštanta/výkon 20).For membrane preparation, cells were adjusted to a concentration of 10 8 cells / ml buffer (50 mM tris-HCl buffer, pH 7.4) and then disintegrated by ultrasound (Branson Sonifier 250.40 to 70 seconds / constant / power 20).
Skúšky väzbovostiBonding tests
Pre skúšky väzbovosti ETA a ETB receptora sa membrány suspendovali v inkubačnom pufre (50 mM tris—HCI, pH 7,4 s 5 mM MnCI2, 40 pg/ml bacitracínu a 0,2 % BSA) v koncentrácii 50 pg proteínu na skúšobné zmes a inkubovali sa pri teplote 25 °C s 25 pM [125J]—ET-ι (skúška ETA receptora) alebo 25 pM [125J]-ET3 (skúška ETb receptora) v prítomnosti a bez prítomnosti testovanej látky. Nešpecifická väzbovosť sa stanovila s 10_7M ET-ι. Po 30 minútach sa filtráciou cez GF/B filtre so sklenenou vatou (Whatman, England) v Skatron kolektore buniek (Skatron, Lier, Norway) oddelili voľné rádioligandy od viazaných rádioligandov a filtre sa premyli s ľadovo chladným tris-HCI pufrom, pH 7,4 s 0,2 % BSA. Rádioaktivita zachytená na filtroch sa kvantifikovala s použitím Packard 2200 CA kvapalného scintilačného počítača.For ET A and ET B receptor binding assays, membranes were suspended in incubation buffer (50 mM tris-HCl, pH 7.4 with 5 mM MnCl 2 , 40 µg / ml bacitracin and 0.2% BSA) at a concentration of 50 µg protein per well. assay mixture and incubated at 25 ° C with 25 µM [ 125 J] -ET 3 (ETA receptor assay) or 25 µM [ 125 J] -ET 3 (ET b receptor assay) in the presence and absence of test substance. Non-specific binding was determined with 10 7 M ET- γ . After 30 minutes, free radioligands were separated from bound radioligands by filtration through GF / B glass wool filters (Whatman, England) in a Skatron collector cell (Skatron, Lier, Norway) and the filters were washed with ice-cold tris-HCl buffer, pH 7, 4 with 0.2% BSA. The radioactivity retained on the filters was quantified using a Packard 2200 CA liquid scintillation counter.
-15Testy na ET antagonisty in vivo:-15Test for ET antagonists in vivo:
Samce SD potkanov s hmotnosťou 250 až 300 g sa anestetizovali s amobarbitalom, umelo ventilovali, vagotomizovali a prepichla sa miecha. Krčná artéria a jugulárna žila sa katetrizovali.Male SD rats weighing 250-300 g were anesthetized with amobarbital, artificially ventilated, vagotomized, and punctured with the spinal cord. The carotid artery and jugular vein were catheterized.
Intravenózne podávanie 1 pg/kg ETi kontrolným zvieratám viedlo k zreteľnému zvýšeniu krvného tlaku, ktoré pretrvávalo počas zdĺhavého obdobia.Intravenous administration of 1 µg / kg ETi to control animals resulted in a marked increase in blood pressure that persisted over a prolonged period.
Testovaným zvieratám sa intravenózne podávali injekcie (1 ml/kg) testovaných zlúčenín 30 minút pred podávaním ET-ι. Na stanovenie ET-antagonistických vlastností sa zmeny krvného tlaku testovaných zvierat porovnávali s hodnotami pre kontrolné zvieratá.Test animals were injected intravenously (1 ml / kg) of test compounds 30 minutes prior to ET-1 administration. To determine ET-antagonistic properties, the blood pressure changes of the test animals were compared with the values for the control animals.
Orálne testovanie zmesných ETa a ETb antagonistov:Oral testing of mixed ETa and ETb antagonists:
Samce normotenzívnych potkanov (Sprague Dawley, Janvier) s hmotnosťou 250 až 350 g sa predošetrili s testovanou zlúčeninou. O 80 minút neskôr sa zvieratá anestetizovali s uretánom a krčná artéria (na meranie krvného tlaku) a jugulárna žila (podávanie hrubého endotelín/endotelín 1) sa katetrizovali.Male normotensive rats (Sprague Dawley, Janvier) weighing 250-350 g were pretreated with the test compound. 80 minutes later, the animals were anesthetized with urethane and the carotid artery (for blood pressure measurement) and the jugular vein (administration of gross endothelin / endothelin 1) was catheterized.
Po období stabilizácie sa hrubý endotelín (20 pg/kg, podávaný objem 0,5 ml/kg) o E^ (0,3 pg/kg, podávaný objem 0,5 ml/kg) sa podávali intravenózne. Krvný tlak a srdcová frekvencia sa zaznamenávali kontinuálne počas 30 minút. Výrazné a dlhotrvajúce zmeny krvného tlaku sa vypočítali ako plocha pod krivkou (AUC). Na stanovenie antagonistických účinkov testovaných látok sa AUC pre zvieratá ošetrené s látkou porovnali s AUC pre kontrolné zvieratá.After the stabilization period, coarse endothelin (20 µg / kg, 0.5 ml / kg administered volume) and E 2 (0.3 µg / kg, 0.5 ml / kg administered volume) were administered intravenously. Blood pressure and heart rate were recorded continuously for 30 minutes. Significant and prolonged changes in blood pressure were calculated as area under the curve (AUC). To determine the antagonist effects of the test substances, the AUC for the treated animals was compared to the AUC for the control animals.
Zlúčeniny podľa vynálezu sa môžu podávať orálne alebo parenterálne (subkutánne, intravenózne, intramuskulárne, intraperitoneálne) konvenčným spôsobom. Podávanie sa môže tiež uskutočňovať s použitím aerosolov alebo sprejov cez nosohltanový priestor.The compounds of the invention may be administered orally or parenterally (subcutaneously, intravenously, intramuscularly, intraperitoneally) by conventional means. Administration can also be accomplished using aerosols or sprays through the nasopharynx space.
Dávka závisí od veku, stavu a hmotnosti pacienta a od spôsobu podávania.The dose depends on the age, condition and weight of the patient and the route of administration.
Denná dávka účinnej zlúčeniny predstavuje zvyčajne približne 0,5 až 50 mg/kg telesnej hmotnosti pri orálnom podávaní a približne 0,1 až 10 mg/kg telesnej hmotnosti pri parenterálnom podávaní.The daily dose of the active compound is usually about 0.5 to 50 mg / kg body weight for oral administration and about 0.1 to 10 mg / kg body weight for parenteral administration.
-16Nové zlúčeniny sa môžu použiť v konvenčných pevných alebo kvapalných farmaceutických formách, napríklad ako nepoťahované alebo (filmom)poťahované tablety, kapsule, prášky, granule, čipky, roztoky, masti, krémy alebo spreje. Tieto sa pripravujú konvenčným spôsobom. Účinné zložky sa na tento účel môžu spracovať s bežnými farmaceutickými pomocnými látkami, ako sú spojivá tabliet, plnidlá, konzervačné prísady, dezintegrátory tabliet, regulátory tečenia, plastifikátory, zmáčacie činidlá, dispergačné činidlá, emulgačné činidlá, rozpúšťadlá, činidlá spomaľujúce uvoľňovanie, antioxidanty a/alebo hnacie plyny (porovnaj H. Sucker a kol.: Pharmazeutische Technológie, Thieme-Verlag, Stuttgart, 1991). Dávkové formy získané týmto spôsobom bežne obsahujú od 0,1 do 90 % hmotnostných účinnej zložky.The novel compounds can be used in conventional solid or liquid pharmaceutical forms, for example, as uncoated or (film) coated tablets, capsules, powders, granules, lace, solutions, ointments, creams or sprays. These are prepared in a conventional manner. For this purpose, the active ingredients may be formulated with conventional pharmaceutical excipients such as tablet binders, fillers, preservatives, tablet disintegrators, flow regulators, plasticizers, wetting agents, dispersing agents, emulsifying agents, solvents, delaying agents, antioxidants and / or or propellants (cf. H. Sucker et al., Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1991). The dosage forms obtained in this manner normally contain from 0.1 to 90% by weight of the active ingredient.
Príklady uskutočnenia vynálezu Príklad 1EXAMPLES Example 1
Metylester kyseliny 2,3-epoxy-3,6-difenylhexánovej2,3-epoxy-3,6-diphenylhexanoic acid methyl ester
1,4 g (31 mmol) 50 % hydridu sodného sa po častiach v priebehu 8 hodín pridalo do roztoku 4 g (17,8 mmol) 1,4-difenyl-1-butanónu a 2,7 ml (31 mmol) metylesteru kyseliny chlóroctovej v 60 ml THF. Po úplnom zreagovaní ketónu sa reakčná zmes pridala do zmesi ľad-voda a extrahovala sa s éterom. Organická fáza sa vysušila nad síranom horečnatým a po oddestilovaní rozpúšťadla sa izolovalo 5,5 g oleja, ktorý sa zobral do ďalšej reakcie.1.4 g (31 mmol) of 50% sodium hydride were added portionwise over 8 hours to a solution of 4 g (17.8 mmol) of 1,4-diphenyl-1-butanone and 2.7 ml (31 mmol) of methyl acid ester. chloroacetic acid in 60 ml THF. After the ketone was fully reacted, the reaction mixture was added to ice-water and extracted with ether. The organic phase was dried over magnesium sulphate and after distilling off the solvent, 5.5 g of an oil were isolated, which was taken on to the next reaction.
Príklad 2Example 2
Metylester kyseliny 2-hydroxy-3-metoxy-3,6-difenylhexánovej g (6,75 mmol) metylesteru kyseliny 2,3-epoxy-3,6-difenylhexánovej sa predložilo s 0,5 ml metanolu v 20 ml dichlórmetánu a pridalo sa 5 kvapiek dietyléterátu fluoridu boritého. Po 2 hodinách sa zmes zahustila a zvyšok sa prečistil pomocou MPLC (gradient cyklohexán/etylacetát), pričom sa izolovalo 530 mg jedného diastereoizoméru, 720 mg druhého diastereoizoméru a 800 mg zmesnej frakcie.2-Hydroxy-3-methoxy-3,6-diphenylhexanoic acid methyl ester g (6.75 mmol) of 2,3-epoxy-3,6-diphenylhexanoic acid methyl ester was added with 0.5 ml of methanol in 20 ml of dichloromethane and added 5 drops of boron trifluoride diethyl etherate. After 2 hours the mixture was concentrated and the residue was purified by MPLC (cyclohexane / ethyl acetate gradient) to isolate 530 mg of one diastereoisomer, 720 mg of the other diastereoisomer and 800 mg of the mixed fraction.
-17Príklad 3-17Example 3
2-Hydroxy-3-metoxy-3,6-difenylhexánová kyselina (jeden diastereoizomér, stereohémia neznáma)2-Hydroxy-3-methoxy-3,6-diphenylhexanoic acid (single diastereoisomer, stereohemia unknown)
Druhý diastereoizomér (720 mg, 2,2 mmol) sa rozpustil v 9 ml dioxánu a pridalo sa 4,5 ml 1 N roztoku hydroxidu sodného. Zmes sa miešala počas 16 hodín a potom, po pridaní vody, sa extrahovala s éterom. Vodná fáza sa okyslila s kyselinou citrónovou a extrahovala sa s éterom, organická fáza sa vysušila nad síranom horečnatým a rozpúšťadlo sa oddestilovalo. Izolovalo sa 936 mg oleja, ktorý sa bezprostredne nechal reagovať v ďalšej reakcii.The second diastereoisomer (720 mg, 2.2 mmol) was dissolved in 9 mL of dioxane and 4.5 mL of 1 N sodium hydroxide solution was added. The mixture was stirred for 16 hours and then, after addition of water, extracted with ether. The aqueous phase was acidified with citric acid and extracted with ether, the organic phase was dried over magnesium sulphate and the solvent was distilled off. 936 mg of an oil were isolated and immediately reacted in the next reaction.
Príklad 4Example 4
2-(4-Metoxy-6-metyl-2-pyrimidinyloxy)-3-metoxy-3,6-difenylhexánová kyselina (jeden diastereoizomér)2- (4-Methoxy-6-methyl-2-pyrimidinyloxy) -3-methoxy-3,6-diphenylhexanoic acid (one diastereoisomer)
195 mg (4,4 mmol) 50 % hydridu sodného, 465 mg (1,5 mmol) kyseliny 2hydroxy-3-metoxy-3,6-difenylhexánovej a 291 mg (1,5 mmol) 3,4-dimetyl-2metylsulfon-pyrimidínu sa zmiešalo v 20 ml DMF a miešalo sa pri laboratórnej teplote počas 2 hodín. Reakčná zmes sa pridala k 100 ml ľadu-vody, okyslila sa s kyselinou citrónovou a extrahovala s éterom. Organická fáza sa vysušila so síranom horečnatým a rozpúšťadlo sa oddestilovalo. Zvyšok sa prečistil pomocou MPLC (gradient cyklohexán/ etylacetát), pričom sa izolovalo 103 mg jedného diastereozoméru.195 mg (4.4 mmol) of 50% sodium hydride, 465 mg (1.5 mmol) of 2-hydroxy-3-methoxy-3,6-diphenylhexanoic acid and 291 mg (1.5 mmol) of 3,4-dimethyl-2-methylsulfone- The pyrimidine was mixed in 20 ml DMF and stirred at room temperature for 2 hours. The reaction mixture was added to 100 mL ice-water, acidified with citric acid and extracted with ether. The organic phase was dried with magnesium sulfate and the solvent was distilled off. The residue was purified by MPLC (cyclohexane / ethyl acetate gradient) to isolate 103 mg of one diastereomer.
1H-NMR (200 MHz, CDCI3): 7,1 - 7,5 ppm (10 H, m), 6,2 (1 H, s), 5,6 (1 H, s), 3,8 (3 H, s), 3,3 (3 H, s), 2,5 - 2,8 (3 H, m), 2,3 (3 H, s), 2,0 (1 H, m), 1,5 - 1,8 (2 H, m). 1 H-NMR (200 MHz, CDCl 3 ): 7.1-7.5 ppm (10H, m), 6.2 (1H, s), 5.6 (1H, s), 3.8 (3H, s), 3.3 (3H, s), 2.5-2.8 (3H, m), 2.3 (3H, s), 2.0 (1H, m) , 1.5-1.8 (2H, m).
ESI MS: M+ = 436ESI MS: M < + > = 436
Príklad 5Example 5
Metylester kyseliny 2,3-epoxy-3-fenyl-6-(3,4-metoxyfenyl)hexánovej (zmes diastereoizomérov):2,3-epoxy-3-phenyl-6- (3,4-methoxyphenyl) hexanoic acid methyl ester (mixture of diastereoisomers):
12,6 g (44 mmol) 1-fenyl-4-(3,4-dimetoxy)fenyl-1-butanónu sa rozpustilo spolu s 8,3 g metylesteru kyseliny chlóroctovej v 50 ml DMF a pri laboratórnej teplote sa12.6 g (44 mmol) of 1-phenyl-4- (3,4-dimethoxy) phenyl-1-butanone were dissolved together with 8.3 g of methyl chloroacetate in 50 ml of DMF and at room temperature
-18po častiach v priebehu 1 hodiny pridalo 3,7 g 50 % suspenzie hydridu sodného. Reakcia prekurzora bola ukončená po celkom 1,5 hodine a reakčný roztok sa pridal k 300 ml zmesi ľad-voda. Vodná fáza sa okyslila s kyselinou citrónovou a extrahovala sa niekoľkokrát s éterom, a organická fáza sa oddelila, premyla a vysušila nad síranom horečnatým. Rozpúšťadlo sa oddestilovalo, čím sa izolovalo 13 g oleja, ktorý sa mohol bezprostredne použiť v ďalšej reakcii.-18 3.7 g of 50% sodium hydride suspension were added in portions over 1 hour. The precursor reaction was complete after a total of 1.5 hours and the reaction solution was added to 300 mL of ice-water. The aqueous phase was acidified with citric acid and extracted several times with ether, and the organic phase was separated, washed and dried over magnesium sulfate. The solvent was distilled off to recover 13 g of an oil which could be used immediately in the next reaction.
Príklad 6Example 6
Metylester kyseliny 2-hydroxy-3-(2-(3,4-dimetoxyfenyl)etoxy)-3-fenyl-6-(3,4-dimetoxyfenyl)hexánovej2-Hydroxy-3- (2- (3,4-dimethoxyphenyl) ethoxy) -3-phenyl-6- (3,4-dimethoxyphenyl) hexanoic acid methyl ester
Zmes 3,6 g (10 mmol) metylesteru kyseliny 2,3-epoxy-3-fenyl-6-(3,4metoxyfenyl)hexánovej, 1,8 g (10 mmol) 2-(3,4-dimetoxy)etanolu a 100 mg kyseliny p-toluénsulfónovej v 50 ml dichlórmetánu sa miešala počas jednej hodiny za chladenia ľadom. Reakčný roztok sa pridal k nasýtenému roztoku hydrogénuhličitanu sodného a organická fáza sa oddelila a vysušila nad síranom horečnatým. Rozpúšťadlo sa oddestilovalo a 4,7 g zvyšku sa prečistilo pomocou MPLC (gradient: cyklohexán/etyl-acetát), čím sa izolovalo 750 mg zmesi diastereoizomérov.A mixture of 3.6 g (10 mmol) of 2,3-epoxy-3-phenyl-6- (3,4-methoxyphenyl) hexanoic acid methyl ester, 1.8 g (10 mmol) of 2- (3,4-dimethoxy) ethanol and 100 g of methyl ester. mg of p-toluenesulfonic acid in 50 ml of dichloromethane was stirred for 1 hour under ice-cooling. The reaction solution was added to saturated sodium bicarbonate solution and the organic phase was separated and dried over magnesium sulfate. The solvent was distilled off and 4.7 g of the residue was purified by MPLC (gradient: cyclohexane / ethyl acetate) to isolate 750 mg of a mixture of diastereoisomers.
Príklad 7Example 7
2-Hydroxy-3-(2-(3,4-dimethoxyfenyl)etoxy)-3-fenyl-6-(3,4-dimetoxyfenyl)hexánová kyselina2-Hydroxy-3- (2- (3,4-dimethoxyphenyl) ethoxy) -3-phenyl-6- (3,4-dimethoxyphenyl) hexanoic acid
2,1 ml 1 N roztoku hydroxidu sodného sa pridalo k 750 mg (1,4 mmol) metylesteru kyseliny 2-hydroxy-3-(2-(3,4-dimetoxyfenyl)etoxy)-3-fenyl-6-(3,4-dimetoxyfenyl)hexánovej rozpustenej v 4,2 ml dioxánu a zmes sa miešala pri laboratórnej teplote počas 16 hodín. K zmesi sa potom 100 ml vody a zmes sa potom extrahovala s éterom. Následne sa neutralizovala s kyselinou chlorovodíkovou, vodná fáza sa extrahovala s éterom, éterová fáza sa vysušila so síranom horečnatým a rozpúšťadlo sa oddestilovalo. Izolovalo sa 620 mg oleja, ktorý sa bezprostredne použil do ďalšej reakcie.2.1 ml of 1 N sodium hydroxide solution was added to 750 mg (1.4 mmol) of 2-hydroxy-3- (2- (3,4-dimethoxyphenyl) ethoxy) -3-phenyl-6- (3, methyl ester) methyl ester. 4-dimethoxyphenyl) hexane dissolved in 4.2 ml dioxane and the mixture was stirred at room temperature for 16 hours. The mixture was then treated with 100 mL of water and extracted with ether. Subsequently, it was neutralized with hydrochloric acid, the aqueous phase was extracted with ether, the ether phase was dried with magnesium sulfate and the solvent was distilled off. 620 mg of an oil were isolated and used immediately for the next reaction.
-19Príklad 8-19Example 8
Kyselina 2-(4,6-dimetyl-2-pyrimidinyloxy)-3-(2-(3,4-dimetoxyfenyl)etoxy)-3-fenyl-6(3,4-dimetoxyfenyl)hexánová2- (4,6-Dimethyl-2-pyrimidinyloxy) -3- (2- (3,4-dimethoxyphenyl) ethoxy) -3-phenyl-6- (3,4-dimethoxyphenyl) hexanoic acid
164 mg (3,42 mmol) hydridu sodného, 600 mg (1,14 mmol) 2-hydroxy-3-(2(3,4-dimetoxyfenyl)etoxy)-3-fenyl- 6-(3,4-dimetoxyfenyl)hexánovej kyseliny a 223 mg (1,2 mmol) 3,4-dimetyl-2-metylsulfonpyrimidínu sa zmiešalo v 10 ml DMF a zmes sa miešala pri laboratórnej teplote počas 6 hodín. Reakčná zmes sa pridala k 100 ml zmesi ľad-voda, okyslila sa s kyselinou citrónovou a extrahovala s éterom. Organická fáza sa vysušila so síranom horečnatým a rozpúšťadlo sa oddestilovalo. Zvyšok sa prečistil okamžitou chromatografiou (gradient cyklohexán/etylacetát), pričom sa izolovalo 115 mg jedného kryštalického diastereoiozméru.164 mg (3.42 mmol) of sodium hydride, 600 mg (1.14 mmol) of 2-hydroxy-3- (2- (3,4-dimethoxyphenyl) ethoxy) -3-phenyl-6- (3,4-dimethoxyphenyl) hexanoic acid and 223 mg (1.2 mmol) of 3,4-dimethyl-2-methylsulfonopyrimidine were mixed in 10 mL of DMF and stirred at room temperature for 6 hours. The reaction mixture was added to 100 mL ice-water, acidified with citric acid and extracted with ether. The organic phase was dried with magnesium sulfate and the solvent was distilled off. The residue was purified by flash chromatography (cyclohexane / ethyl acetate gradient) to isolate 115 mg of one crystalline diastereoisomer.
Diastereoizomér I:Diastereoisomer I:
Teplota topenia: 93 až 96 °CMelting point: 93-96 ° C
ESI MS: M+ = 630ESI MS: M < + > = 630
Príklad 9Example 9
Kyselina 2-(4I6-dimetyl-2-pyrimidinyloxy)-3-(3)4-dimetoxybenzyloxy)-3-fenyl-6-(3,4dimetoxyfenyl)hexánová2- (4 I 6-dimethyl-2-pyrimidinyloxy) -3- (3) 4-dimethoxy) -3-phenyl-6- (3,4-Dimethoxyphenyl) hexanoic acid
Diastereoizomér I:Diastereoisomer I:
Teplota topenia: 130 až 133 °CMelting point: 130-133 ° C
ESI MS: M+ = 616ESI MS: M < + > = 616
Príklad 10Example 10
Kyselina 2-(4,6-dimetyl-2-pyrimidinyloxy)-3-(4-metoxyfenoxy)-3-fenyl-6-(3,4-dimetoxyfenyl)hexánová2- (4,6-Dimethyl-2-pyrimidinyloxy) -3- (4-methoxyphenoxy) -3-phenyl-6- (3,4-dimethoxyphenyl) hexanoic acid
Diastereoizomér I:Diastereoisomer I:
Teplota topenia: 118 až 122 °CMelting point: 118-122 ° C
ESI MS: M+ = 572ESI MS: M < + > = 572
-20Príklad 11-20Example 11
Kyselina 2-(4,6-dimetyl-2-pyrimidinyloxy)-3-metoxy-3-fenyl-6-(3,4-di-metoxyfenyl)hexánová2- (4,6-Dimethyl-2-pyrimidinyloxy) -3-methoxy-3-phenyl-6- (3,4-dimethoxyphenyl) hexanoic acid
Diastereoizomér I:Diastereoisomer I:
Teplota topenia: 135 až 138 °CMelting point: 135-138 ° C
ESI MS: M+ = 480ESI MS: M < + > = 480
Diastereoizomér II:Diastereoisomer II:
Teplota topenia: 128-134°CM.p .: 128-134 ° C
ESI MS: M+ = 480ESI MS: M < + > = 480
Príklad 12Example 12
Kyselina 2-(4,6-dimetyl-2-pyrimidinyloxy)-3-metoxy-3,6-difenylhexánová 1H-NMR (200 MHz, CDCI3): 7,1 - 7,5 ppm (10 H, m), 6,7 (1 H, s), 5,8 (1 H, s), 3,3 (3 H, s), 2,5 - 2,7 (3 H, m), 2,3 (6 H, s), 2,0 - 2,1 (1 H, m), 1,6 - 1,8 (2 H, m).2- (4,6-Dimethyl-2-pyrimidinyloxy) -3-methoxy-3,6-diphenylhexanoic acid 1 H-NMR (200 MHz, CDCl 3 ): 7.1-7.5 ppm (10H, m) , 6.7 (1H, s), 5.8 (1H, s), 3.3 (3H, s), 2.5-2.7 (3H, m), 2.3 (6H) H, s), 2.0-2.1 (1H, m), 1.6-1.8 (2H, m).
ESI MS: M+ = 420ESI MS: M < + > = 420
Príklad 13Example 13
Kyselina 2-(4,6-dimetyl-2-pyrimidinyloxy)-3-hex-3E-enoxy-3,6-difenylhexánová Diastereoizomér I:2- (4,6-Dimethyl-2-pyrimidinyloxy) -3-hex-3E-enoxy-3,6-diphenylhexanoic acid Diastereoisomer I:
Teplota topenia: 110 až 114 °CMelting point: 110-114 ° C
ESI MS: M+ = 488ESI MS: M < + > = 488
Diastereoizomér li:Diastereoisomer li:
ESI MS: M+ = 488ESI MS: M < + > = 488
Príklad 14Example 14
Kyselina 2-(4,6-dimetyl-2-pyrimidinyloxy)-3-(2-(3,4-dimetoxyfenyl)etoxy)-316-difenylhexánová2- (4,6-dimethyl-2-pyrimidinyloxy) -3- (2- (3,4-dimethoxyphenyl) ethoxy) -3-diphenyl-1 6
-21 Diastereoizomér I:-21 Diastereoisomer I:
Teplota topenia: 87 až 88 °CMelting point: 87-88 ° C
ESI MS: M+ = 570ESI MS: M < + > = 570
Diastereoizomér II:Diastereoisomer II:
Teplota topenia: 87 až 88 °CMelting point: 87-88 ° C
ESI MS: M+ = 570ESI MS: M < + > = 570
Príklad 15Example 15
Kyselina 2-(4-metoxy-6-metyl-2-pyrimidinyloxy)-3-(2-(3,4-dimetoxyfenyl)etoxy)-3,6difenylhexánová2- (4-Methoxy-6-methyl-2-pyrimidinyloxy) -3- (2- (3,4-dimethoxyphenyl) ethoxy) -3,6-diphenylhexanoic acid
Diastereoizomér I:Diastereoisomer I:
Teplota topenia: 141 až 142 °CM.p .: 141-142 ° C
ESI MS: M+ = 586ESI MS: M < + > = 586
Príklad 16Example 16
Kyselina 2-(4,6-dimetyl-2-pyrimidinyloxy)-3-(3,4-dimetoxybenzyloxy)-3,6-difenyl-hexánová2- (4,6-Dimethyl-2-pyrimidinyloxy) -3- (3,4-dimethoxybenzyloxy) -3,6-diphenylhexanoic acid
Diastereoizomér I:Diastereoisomer I:
1H-NMR (200 MHz, CDCI3): 7,1 - 7,5 ppm (10 H, m), 6,9 (3 H, m),6,7 (1 H, s), 5,8 (1 H, s), 4,4 (1 H, d), 4,3 (1 H, d), 3,9 (3 H, s), 3,85 (3 H, s), 2,5 - 2,7 (3 H, m), 2,3 (6 H, s), 2,0-2,3(1 H, m), 1,7-1,9 (2 H, m). 1 H-NMR (200 MHz, CDCl 3 ): 7.1-7.5 ppm (10H, m), 6.9 (3H, m), 6.7 (1H, s), 5.8 (1H, s), 4.4 (1H, d), 4.3 (1H, d), 3.9 (3H, s), 3.85 (3H, s), 2.5 2.7 (3H, m), 2.3 (6H, s), 2.0-2.3 (1H, m), 1.7-1.9 (2H, m).
ESI MS: M+ = 556ESI MS: M < + > = 556
Príklad 17Example 17
Kyselina 2-(4-metoxy-6-metyl-2-pyrimidinyloxy)-3-(3,4-dimetoxybenzyloxy)-3,6-difenylhexánová2- (4-Methoxy-6-methyl-2-pyrimidinyloxy) -3- (3,4-dimethoxybenzyloxy) -3,6-diphenylhexanoic acid
Diastereoizomér I:Diastereoisomer I:
-221H-NMR (200 MHz, CDCI3): 7,1 - 7,5 ppm (10 H, m), 6,9 (3 H, m), 6,25 (1 H, s), 5,75 (1 H, s), 4,45 (1 H, d), 4,35 (1 H, d), 3,9 (3 H, s), 3,85 (6 H, s), 2,4 - 2,7 (3 H, m), 2,3 (6 H, s), 2,0 - 2,2 (1 H, m), 1,7 - 1,9 (2 H, m).-22 1 H-NMR (200 MHz, CDCl3): 7.1 to 7.5 ppm (10H, m), 6.9 (3H, m), 6.25 (1H, s), 5 , 75 (1H, s), 4.45 (1H, d), 4.35 (1H, d), 3.9 (3H, s), 3.85 (6H, s), 2 , 4-2.7 (3H, m), 2.3 (6H, s), 2.0-2.2 (1H, m), 1.7-1.9 (2H, m) .
ESI MS: M+ = 572ESI MS: M < + > = 572
Príklad 18Example 18
Kyselina 2-(4-metoxy-6-metyl-2-pyrimidinyloxy)-3-(2-(2-tiofenyletoxy)-3,6-difenylhexánová2- (4-Methoxy-6-methyl-2-pyrimidinyloxy) -3- (2- (2-thiophenylethoxy) -3,6-diphenylhexanoic acid)
Zmes diastereoizomérov 3:1:3: 1 diastereoisomer mixture:
Rozklad: 85 °CDecomposition: 85 ° C
ESI MS: M+ = 532ESI MS: M < + > = 532
Príklad 19Example 19
Kyselina 2-(4,6-dimetyl-2-pyrimidinyloxy)-3-(2-(3,4,5-trimetoxyfenyl)etoxy)-3,6-difenylhexánová2- (4,6-Dimethyl-2-pyrimidinyloxy) -3- (2- (3,4,5-trimethoxyphenyl) ethoxy) -3,6-diphenylhexanoic acid
Diastereoizomér I:Diastereoisomer I:
1H-NMR (200 MHz, CDCI3): 7,0 - 7,3 ppm (10 H, m), 6,65 (1 H, m), 6,4 (2 H, s), 5,75 (1 H, s), 3,9 (3 H, s), 3,85 (6 H, s), 3,5 - 3,7 (2 H, m), 2,8 - 2,9 (2 H, m), 2,3 - 2,5 (3 H, m), 2,3 (6 H, s), 2,0 - 2,3 (1 H, m), 1,5 - 1,7 (2 H, m). 1 H-NMR (200 MHz, CDCl 3 ): 7.0-7.3 ppm (10H, m), 6.65 (1H, m), 6.4 (2H, s), 5.75 (1H, s), 3.9 (3H, s), 3.85 (6H, s), 3.5-3.7 (2H, m), 2.8-2.9 (2 H, m), 2.3-2.5 (3H, m), 2.3 (6H, s), 2.0-2.3 (1H, m), 1.5-1.7 (2H, m).
ESI MS: M+ = 600ESI MS: M < + > = 600
Príklad 20Example 20
Kyselina 2-(4-metoxy-6-metyl-2-pyrimidinyloxy)-3-(2-(3,4,5-trimetoxyfenyl)etoxy)-3,6difenylhexánová2- (4-Methoxy-6-methyl-2-pyrimidinyloxy) -3- (2- (3,4,5-trimethoxyphenyl) ethoxy) -3,6-diphenylhexanoic acid
Diastereoizomér I:Diastereoisomer I:
Teplota topenia: 153 až 155 °CMp: 153-155 ° C
ESI MS: M+ = 616ESI MS: M < + > = 616
-23Príklad 21-23Example 21
Kyselina 2-(4,6-dimetyl-2-pyrimidinyloxy)-3-(2-(4-hydroxy-3-metoxyfenyl)etoxy)-3,6difenylhexánová2- (4,6-Dimethyl-2-pyrimidinyloxy) -3- (2- (4-hydroxy-3-methoxyphenyl) ethoxy) -3,6-diphenylhexanoic acid
Diastereoizomér I:Diastereoisomer I:
1H-NMR (200 MHz, CDCI3): 7,0 - 7,4 ppm (10 H, m), 6,9 (1 H, dm), 6,6 - 6,75 (3 H, m), 5,8 (1 H, s), 5,5 (OH), 3,9 (3 H, s), 3,85 (3 H, s), 3,5 - 3,7 (2 H, m), 2,8 - 2,9 (2 H, tr), 2,3 - 2,5 (3 H, m), 2,3 (6 H, s), 2,0 - 2,3 (1 H, m), 1,5 - 1,7 (2 H, m). 1 H-NMR (200 MHz, CDCl 3 ): 7.0-7.4 ppm (10H, m), 6.9 (1H, dm), 6.6-6.75 (3H, m) , 5.8 (1H, s), 5.5 (OH), 3.9 (3H, s), 3.85 (3H, s), 3.5-3.7 (2H, m) ), 2.8-2.9 (2H, tr), 2.3-2.5 (3H, m), 2.3 (6H, s), 2.0-2.3 (1H) , m), 1.5-1.7 (2H, m).
ESI MS: M+ = 556ESI MS: M < + > = 556
Diastereoizomér II:Diastereoisomer II:
ESI MS: M+ = 556ESI MS: M < + > = 556
Príklad 22Example 22
Kyselina 2-(4-metoxy-6-metyl-2-pyrimidinyloxy)-3-(2-(4-hydroxy-3-metoxyfenyl)etoxy)3,6-difenylhexánová2- (4-Methoxy-6-methyl-2-pyrimidinyloxy) -3- (2- (4-hydroxy-3-methoxyphenyl) ethoxy) 3,6-diphenylhexanoic acid
Diastereoizomér I:Diastereoisomer I:
Teplota topenia: 154 až 157 °CMp .: 154-157 ° C
ESI MS: M+ = 572ESI MS: M < + > = 572
Príklad 23Example 23
Kyselina 2-(4,6-dimetyl-2-pyrimidinyloxy)-3-(4-karboxybenzyloxy)-3,6-difenylhexánová2- (4,6-Dimethyl-2-pyrimidinyloxy) -3- (4-carboxybenzyloxy) -3,6-diphenylhexanoic acid
Diastereoizomér I:Diastereoisomer I:
1H-NMR (200 MHz, CDCI3): 8,0 (2 H, d), 7,1 - 7,5 ppm (12 H, m), 6,8 (1 H, m), 6,8 (1 1 H-NMR (200 MHz, CDCl 3 ): 8.0 (2H, d), 7.1-7.5 ppm (12H, m), 6.8 (1H, m), 6.8 (1
H, s), 4,6 (1 H, d), 4,5 (1 H, d), 2,5 - 2,7 (3 H, m), 2,3 (6 H, s), 2,1 - 2,25 (1 H, m),H, s), 4.6 (1H, d), 4.5 (1H, d), 2.5-2.7 (3H, m), 2.3 (6H, s), 2 1 - 2.25 (1H, m),
I, 5-1,7 (2 H, m).1.5-1.7 (2H, m).
ESI MS: M+ = 540ESI MS: M < + > = 540
Diastereoizomér II:Diastereoisomer II:
-24Teplota topenia: 160 až 167 °C-24 Melting point: 160-167 ° C
ESI MS: M+ = 540ESI MS: M < + > = 540
Príklad 24Example 24
Kyselina 2-(4-metoxy-6-metyl-2-pyrimidinyloxy)-3-(4-karboxybenzyloxy)-3,6-difenylhexánová2- (4-Methoxy-6-methyl-2-pyrimidinyloxy) -3- (4-carboxybenzyloxy) -3,6-diphenylhexanoic acid
Diastereoizomér I:Diastereoisomer I:
1H-NMR (200 MHz, CDCI3): 8,0 (2 H, d), 7,1 - 7,5 ppm (12 H, m), 6,2 (1 H, m), 5,6 (1 H, s), 4,55 (1 H, d), 4,45 (1 H, d), 3,9 (3 H, s), 2,5 - 2,7 (3 H, m), 2,3 (3 H, s), 2,1 2,25 (1 H, m), 1,6-1,8(2 H, m). 1 H-NMR (200 MHz, CDCl 3 ): 8.0 (2H, d), 7.1-7.5 ppm (12H, m), 6.2 (1H, m), 5.6 (1H, s), 4.55 (1H, d), 4.45 (1H, d), 3.9 (3H, s), 2.5-2.7 (3H, m) 2.3 (3H, s), 2.1 2.25 (1H, m), 1.6-1.8 (2H, m).
ESI MS: M+ = 556ESI MS: M < + > = 556
Diastereoizomér II:Diastereoisomer II:
ESI MS: M+ = 556ESI MS: M < + > = 556
Príklad 25Example 25
Kyselina 2-(4,6-dimetyl-2-pyrimidinyloxy)-3-(4-metoxyfenoxy)-3,6-difenylhexánová2- (4,6-Dimethyl-2-pyrimidinyloxy) -3- (4-methoxyphenoxy) -3,6-diphenylhexanoic acid
Diastereoizomér I:Diastereoisomer I:
1H-NMR (200 MHz, CDCI3): 7,1 - 7,5 ppm (10 H, m), 6,5 - 6,8 (5 H, m), 5,9 (1 H, s), 3,75 (3 H, s), 2,2 - 2,7 (4 H, m), 2,3 (6 H, s), 1,5 -1,7 (2 H, m). 1 H-NMR (200 MHz, CDCl 3 ): 7.1-7.5 ppm (10H, m), 6.5-6.8 (5H, m), 5.9 (1H, s) 3.75 (3H, s), 2.2-2.7 (4H, m), 2.3 (6H, s), 1.5-1.7 (2H, m).
ESI MS: M+ = 512ESI MS: M < + > = 512
Diastereoizomér II:Diastereoisomer II:
ESI MS: M+ = 512ESI MS: M < + > = 512
Príklad 26Example 26
Kyselina 2-(4-metoxy-6-metyl-2-pyrimidinyloxy)-3-(4-metoxyfenoxy)-3,6-difenylhexánová2- (4-Methoxy-6-methyl-2-pyrimidinyloxy) -3- (4-methoxyphenoxy) -3,6-diphenylhexanoic acid
Diastereoizomér I:Diastereoisomer I:
1H-NMR (200 MHz, CDCI3): 7,1 - 7,5 ppm (10 H, m), 6,5 - 6,9 (4 H, m), 6,2 (1 H, s), 5,75 (1 H, s), 3,8 (3 H, s), 3,75 (3 H, s), 2,2 - 2,7 (4 H, m), 2,3 (3 H, s), 1,5 -1,7 (2 H, m). 1 H-NMR (200 MHz, CDCl 3 ): 7.1-7.5 ppm (10H, m), 6.5-6.9 (4H, m), 6.2 (1H, s) , 5.75 (1H, s), 3.8 (3H, s), 3.75 (3H, s), 2.2-2.7 (4H, m), 2.3 (3H, s) H, s), 1.5-1.7 (2H, m).
-25ESI MS: M+ = 528-25ESI MS: M < + > = 528
Diastereoizomér II:Diastereoisomer II:
ESI MS: M+ = 528ESI MS: M < + > = 528
Príklad 27Example 27
Kyselina 2-(4,6-dimetyl-2-pyrimidinyloxy)-3-(3-(3,4,5-trimetoxyfenyl)-2E-propenoxy)3,6-difenylhexánová2- (4,6-Dimethyl-2-pyrimidinyloxy) -3- (3- (3,4,5-trimethoxyphenyl) -2E-propenoxy) 3,6-diphenylhexanoic acid
Diastereoizomér I:Diastereoisomer I:
1H-NMR (200 MHz, CDCI3): 7,1 - 7,4 ppm (10 H, m), 6,6 (1 H, s), 6,55 (2 H, s), 6,3 (1 H, s), 6,2 (1 H, dtr), 5,9 (1 H, d), 4,0 - 4,2 (1 H, m), 3,85 (3 H, s), 3,8 (3 H, s), 3,75 (3 H, s), 3,4 (1 H, m), 2,4 - 2,7 (3 H, m), 2,3 (6 H, s), 2,0 - 2,1 (1 H, m), 1,5 -1,7 (2 H, m). 1 H-NMR (200 MHz, CDCl 3 ): 7.1-7.4 ppm (10H, m), 6.6 (1H, s), 6.55 (2H, s), 6.3 (1H, s), 6.2 (1H, dtr), 5.9 (1H, d), 4.0-4.2 (1H, m), 3.85 (3H, s) 3.8 (3H, s), 3.75 (3H, s), 3.4 (1H, m), 2.4-2.7 (3H, m), 2.3 (6H) H, s), 2.0-2.1 (1H, m), 1.5-1.7 (2H, m).
ESI MS: M+ = 612ESI MS: M < + > = 612
Zlúčeniny uvedené v tabuľke 1 sa môžu pripraviť podobným spôsobom ako je opísané vo všeobecnej časti.The compounds listed in Table 1 can be prepared in a similar manner as described in the general section.
cowhat
CQ .·CQ. ·
>. í=“ O>. í = “O
N O n n X (0 O S £· £> Φ Q) i i nN O n n X (0 O S £ · £> Φ Q) i n
s s i is s i i
OJ oi II II * « T- CMOJ II II * «T- CM
-39Príklad 12-39Example 12
Údaje väzby receptora sa merali väzbovou skúškou opísanou vyššie, pre ďalej uvedené zlúčeniny.Receptor binding data was measured by the binding assay described above for the compounds listed below.
Výsledky sú zosumarizované v tabuľke 2.The results are summarized in Table 2.
Tabuľka 2Table 2
Údaje väzby receptora (hodnoty Kj)Receptor Binding Data (K i Values)
-4075/ 454 - 4000-4075 / 454-4000
Claims (2)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19738578A DE19738578A1 (en) | 1997-09-04 | 1997-09-04 | Carboxylic acid derivatives useful as endothelin A and B antagonists also active as renin and angiotensin inhibitors |
DE1998111915 DE19811915A1 (en) | 1998-03-18 | 1998-03-18 | New carboxylic acid derivatives |
PCT/EP1998/005354 WO1999011629A1 (en) | 1997-09-04 | 1998-08-24 | Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
SK1522000A3 true SK1522000A3 (en) | 2000-08-14 |
Family
ID=26039663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK152-2000A SK1522000A3 (en) | 1997-09-04 | 1998-08-24 | Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1009741A1 (en) |
JP (1) | JP2001514254A (en) |
KR (1) | KR20010023615A (en) |
CN (1) | CN1269792A (en) |
AR (1) | AR017052A1 (en) |
AU (1) | AU748610B2 (en) |
BG (1) | BG104222A (en) |
BR (1) | BR9811631A (en) |
CA (1) | CA2302350A1 (en) |
CO (1) | CO4970738A1 (en) |
HR (1) | HRP980484A2 (en) |
HU (1) | HUP0004935A3 (en) |
ID (1) | ID25620A (en) |
IL (1) | IL134276A0 (en) |
NO (1) | NO20001077D0 (en) |
NZ (1) | NZ502660A (en) |
PL (1) | PL338954A1 (en) |
SK (1) | SK1522000A3 (en) |
TR (1) | TR200000602T2 (en) |
TW (1) | TW546295B (en) |
WO (1) | WO1999011629A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19924892A1 (en) * | 1999-06-01 | 2000-12-07 | Basf Ag | New carboxylic acid derivatives with aryl-substituted nitrogen heterocycles, their production and use as endothelin receptor antagonists |
BRPI0711315A2 (en) * | 2006-05-29 | 2011-11-29 | Nicox Sa | compound use of a compound pharmaceutical composition and pharmaceutical kit |
ATE520696T1 (en) | 2008-03-05 | 2011-09-15 | Boehringer Ingelheim Int | TRICYCLIC PYRIDINE DERIVATIVES, MEDICATIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND METHOD FOR THEIR PRODUCTION |
EP2451786B1 (en) * | 2009-07-10 | 2014-01-22 | Cadila Healthcare Limited | Improved process for the preparation of ambrisentan and novel intermediates thereof |
CA2790643A1 (en) | 2010-02-19 | 2011-08-25 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
JP5947382B2 (en) | 2011-08-17 | 2016-07-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Furo [3,4-c] quinoline derivatives, drugs containing such compounds, their use and methods for their preparation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4411225A1 (en) * | 1994-03-31 | 1995-10-05 | Basf Ag | Use of carboxylic acid derivatives as a drug |
DE19533023B4 (en) * | 1994-10-14 | 2007-05-16 | Basf Ag | New carboxylic acid derivatives, their preparation and use |
US6136828A (en) * | 1996-02-01 | 2000-10-24 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
DE19614542A1 (en) * | 1996-04-12 | 1997-10-16 | Basf Ag | New carboxylic acid derivatives, their production and use |
DE19636046A1 (en) * | 1996-09-05 | 1998-03-12 | Basf Ag | New carboxylic acid derivatives, their production and use as mixed ET¶A¶ / ET¶B¶ receptor antagonists |
-
1998
- 1998-08-24 CN CN98808862A patent/CN1269792A/en active Pending
- 1998-08-24 HU HU0004935A patent/HUP0004935A3/en unknown
- 1998-08-24 EP EP98948859A patent/EP1009741A1/en not_active Withdrawn
- 1998-08-24 AU AU95333/98A patent/AU748610B2/en not_active Ceased
- 1998-08-24 SK SK152-2000A patent/SK1522000A3/en unknown
- 1998-08-24 IL IL13427698A patent/IL134276A0/en unknown
- 1998-08-24 PL PL98338954A patent/PL338954A1/en unknown
- 1998-08-24 ID IDW20000386D patent/ID25620A/en unknown
- 1998-08-24 TR TR2000/00602T patent/TR200000602T2/en unknown
- 1998-08-24 BR BR9811631-2A patent/BR9811631A/en not_active IP Right Cessation
- 1998-08-24 CA CA002302350A patent/CA2302350A1/en not_active Abandoned
- 1998-08-24 JP JP2000508669A patent/JP2001514254A/en active Pending
- 1998-08-24 WO PCT/EP1998/005354 patent/WO1999011629A1/en not_active Application Discontinuation
- 1998-08-24 NZ NZ502660A patent/NZ502660A/en unknown
- 1998-08-24 KR KR1020007002264A patent/KR20010023615A/en not_active Withdrawn
- 1998-09-02 HR HR19811915.1A patent/HRP980484A2/en not_active Application Discontinuation
- 1998-09-03 AR ARP980104402A patent/AR017052A1/en not_active Application Discontinuation
- 1998-09-03 CO CO98050561A patent/CO4970738A1/en unknown
- 1998-09-03 TW TW087114595A patent/TW546295B/en active
-
2000
- 2000-03-02 NO NO20001077A patent/NO20001077D0/en not_active Application Discontinuation
- 2000-03-06 BG BG104222A patent/BG104222A/en unknown
Also Published As
Publication number | Publication date |
---|---|
ID25620A (en) | 2000-10-19 |
TR200000602T2 (en) | 2000-12-21 |
CN1269792A (en) | 2000-10-11 |
AU9533398A (en) | 1999-03-22 |
CO4970738A1 (en) | 2000-11-07 |
BR9811631A (en) | 2000-09-26 |
PL338954A1 (en) | 2000-12-04 |
NO20001077L (en) | 2000-03-02 |
EP1009741A1 (en) | 2000-06-21 |
AR017052A1 (en) | 2001-08-22 |
CA2302350A1 (en) | 1999-03-11 |
IL134276A0 (en) | 2001-04-30 |
WO1999011629A1 (en) | 1999-03-11 |
NZ502660A (en) | 2002-02-01 |
KR20010023615A (en) | 2001-03-26 |
HRP980484A2 (en) | 1999-06-30 |
HUP0004935A2 (en) | 2001-10-28 |
BG104222A (en) | 2001-02-28 |
TW546295B (en) | 2003-08-11 |
AU748610B2 (en) | 2002-06-06 |
NO20001077D0 (en) | 2000-03-02 |
JP2001514254A (en) | 2001-09-11 |
HUP0004935A3 (en) | 2001-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK25999A3 (en) | Azinyloxy-and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed eta/etb endothelin receptor antagonists | |
AU731579B2 (en) | Novel alpha-hydroxy acid derivatives, their preparation and use | |
AU711293B2 (en) | Novel carboxylic acid derivatives, their preparation and use | |
SK1522000A3 (en) | Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists | |
SK176299A3 (en) | New 'beta'-amino and 'beta'-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists | |
TW579376B (en) | Novel carboxylic acid derivatives having a 5-substituted pyrimidine ring, their preparation and use | |
AU765345B2 (en) | Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists | |
HUP0201321A2 (en) | New beta-amido and beta-sulfonamidocarboxylic acid derivatives, their production and pharmaceutical preparations containing the compounds | |
SK11752000A3 (en) | Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed eta/etb-receptor antagonists | |
SK772002A3 (en) | Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists | |
SK4932000A3 (en) | Heterocyclically substituted alpha-hydroxycarboxlic acid derivatives, method for producing the same and their use as endothelin receptor antagonists | |
HRP970503A2 (en) | Novel carboxylic acid derivatives, their production and their use as mixed eta/etb receptor antagonists | |
MXPA00001479A (en) | Novel carboxylic acid derivatives, their production and their use as mixed eta | |
HRP20010164A2 (en) | New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists | |
DE19738578A1 (en) | Carboxylic acid derivatives useful as endothelin A and B antagonists also active as renin and angiotensin inhibitors | |
MXPA99001995A (en) | New derivatives of oxilic acid, its obtaining and use in quality of mixed antagonists of receivers eta / | |
CZ2000743A3 (en) | Derivatives of carboxylic acid and their use | |
CZ326298A3 (en) | Carboxylic acid derivatives and their use | |
CZ326198A3 (en) | Novel derivatives of alpha-hydroxy acid, their preparation and use | |
CZ61999A3 (en) | Derivatives of azinyloxy and phenoxy-diaryl-carboxylic acids, process of their preparation and use as mixed antagonists of ETA/ETB endothelin receptors | |
DE19811915A1 (en) | New carboxylic acid derivatives |